1
|
Chasseigneaux S, Cochois-Guégan V, Lecorgne L, Lochus M, Nicolic S, Blugeon C, Jourdren L, Gomez-Zepeda D, Tenzer S, Sanquer S, Nivet-Antoine V, Menet MC, Laplanche JL, Declèves X, Cisternino S, Saubaméa B. Fasting upregulates the monocarboxylate transporter MCT1 at the rat blood-brain barrier through PPAR δ activation. Fluids Barriers CNS 2024; 21:33. [PMID: 38589879 PMCID: PMC11003008 DOI: 10.1186/s12987-024-00526-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Accepted: 02/29/2024] [Indexed: 04/10/2024] Open
Abstract
BACKGROUND The blood-brain barrier (BBB) is pivotal for the maintenance of brain homeostasis and it strictly regulates the cerebral transport of a wide range of endogenous compounds and drugs. While fasting is increasingly recognized as a potential therapeutic intervention in neurology and psychiatry, its impact upon the BBB has not been studied. This study was designed to assess the global impact of fasting upon the repertoire of BBB transporters. METHODS We used a combination of in vivo and in vitro experiments to assess the response of the brain endothelium in male rats that were fed ad libitum or fasted for one to three days. Brain endothelial cells were acutely purified and transcriptionaly profiled using RNA-Seq. Isolated brain microvessels were used to assess the protein expression of selected BBB transporters through western blot. The molecular mechanisms involved in the adaptation to fasting were investigated in primary cultured rat brain endothelial cells. MCT1 activity was probed by in situ brain perfusion. RESULTS Fasting did not change the expression of the main drug efflux ATP-binding cassette transporters or P-glycoprotein activity at the BBB but modulated a restrictive set of solute carrier transporters. These included the ketone bodies transporter MCT1, which is pivotal for the brain adaptation to fasting. Our findings in vivo suggested that PPAR δ, a major lipid sensor, was selectively activated in brain endothelial cells in response to fasting. This was confirmed in vitro where pharmacological agonists and free fatty acids selectively activated PPAR δ, resulting in the upregulation of MCT1 expression. Moreover, dosing rats with a specific PPAR δ antagonist blocked the upregulation of MCT1 expression and activity induced by fasting. CONCLUSIONS Altogether, our study shows that fasting affects a selected set of BBB transporters which does not include the main drug efflux transporters. Moreover, we describe a previously unknown selective adaptive response of the brain vasculature to fasting which involves PPAR δ and is responsible for the up-regulation of MCT1 expression and activity. Our study opens new perspectives for the metabolic manipulation of the BBB in the healthy or diseased brain.
Collapse
Affiliation(s)
- Stéphanie Chasseigneaux
- Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Véronique Cochois-Guégan
- Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Lucas Lecorgne
- Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Murielle Lochus
- Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Sophie Nicolic
- Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Corinne Blugeon
- Département de biologie, GenomiqueENS, Institut de Biologie de l'ENS (IBENS), École normale supérieure, CNRS, INSERM, Université PSL, 75005, Paris, France
| | - Laurent Jourdren
- Département de biologie, GenomiqueENS, Institut de Biologie de l'ENS (IBENS), École normale supérieure, CNRS, INSERM, Université PSL, 75005, Paris, France
| | - David Gomez-Zepeda
- Helmholtz-Institute for Translational Oncology Mainz (HI-TRON Mainz), A Hemlholtz Institute of the DKFZ, Mainz, Germany
- German Cancer Research Center (DKFZ) Heidelberg, Division 191, 69120, Heidelberg, Germany
- Institute of Immunology, University Medical Center of the Johannes-Gutenberg University, Mainz, Germany
| | - Stefan Tenzer
- Helmholtz-Institute for Translational Oncology Mainz (HI-TRON Mainz), A Hemlholtz Institute of the DKFZ, Mainz, Germany
- German Cancer Research Center (DKFZ) Heidelberg, Division 191, 69120, Heidelberg, Germany
- Institute of Immunology, University Medical Center of the Johannes-Gutenberg University, Mainz, Germany
- Research Center for Immunotherapy (FZI), University Medical Center of the Johannes-Gutenberg University, Mainz, Germany
| | | | - Valérie Nivet-Antoine
- AP-HP Biochimie générale, Hôpital Necker Enfants Malades, Université Paris Cité, Inserm, Innovations Thérapeutiques en Hémostase, Paris, France
| | - Marie-Claude Menet
- Institut de Chimie Physique, CNRS UMR8000, Université Paris-Saclay, 91400, Orsay, France
| | - Jean-Louis Laplanche
- Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Xavier Declèves
- Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Salvatore Cisternino
- Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Bruno Saubaméa
- Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm, 4 avenue de l'Observatoire, 75006, Paris, France.
| |
Collapse
|
2
|
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, Arrondeau J, Boudou-Rouquette P, Bretagne MC, Salem JE, Declèves X, Vidal M, Kramkimel N, Guegan S, Aractingi S, Huillard O, Alexandre J, Wislez M, Goldwasser F, Blanchet B. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients. Br J Cancer 2024:10.1038/s41416-024-02659-x. [PMID: 38532102 DOI: 10.1038/s41416-024-02659-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 03/05/2024] [Accepted: 03/12/2024] [Indexed: 03/28/2024] Open
Abstract
BACKGROUND Reducing nivolumab dose intensity could increase patients' life quality and decrease the financial burden while maintaining efficacy. The aims of this study were to develop a population PK model of nivolumab based on data from unselected metastatic cancer patients and to simulate extended-interval regimens allowing to maintain minimal effective plasma concentrations (MEPC). METHODS Concentration-time data (992 plasma nivolumab concentrations, 364 patients) were modeled using a two-compartment model with linear elimination clearance in Monolix software. Extended-interval regimens allowing to maintain steady-state trough concentrations (Cmin,ss) above the MEPC of 2.5 mg/L or 1.5 mg/L in >90% of patients were simulated. RESULTS Increasing 3-times the dosing interval from 240 mg every two weeks (Q2W) to Q6W and 2-times from 480 mg Q4W to Q8W resulted in Cmin,ss above 2.5 mg/L in 95.8% and 95.4% of patients, respectively. 240 mg Q8W and 480 mg Q10W resulted in Cmin,ss above 1.5 mg/L in 91.0% and 91.8% of patients, respectively. Selection of a 240 mg Q6W regimen would decrease by 3-fold the annual treatment costs compared to standard regimen of 240 mg Q2W (from 78,744€ to 26,248€ in France). CONCLUSIONS Clinical trials are warranted to confirm the non-inferiority of extended-interval compared to standard regimen.
Collapse
Affiliation(s)
- Alicja Puszkiel
- Université Paris Cité, Faculté de Pharmacie de Paris, INSERM UMR-S1144, Paris, France.
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France.
| | - Guillaume Bianconi
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France
| | - Blaise Pasquiers
- Université Paris Cité, Faculté de Pharmacie de Paris, INSERM UMR-S1144, Paris, France
- PhinC Development, Massy, France
| | | | - Jennifer Arrondeau
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
| | - Pascaline Boudou-Rouquette
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
| | - Marie-Claire Bretagne
- Department of Pharmacology, Pharmacovigilance Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - Joe-Elie Salem
- Department of Pharmacology, Pharmacovigilance Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
- INSERM, CIC-1901, Sorbonne Université, Paris, France
| | - Xavier Declèves
- Université Paris Cité, Faculté de Pharmacie de Paris, INSERM UMR-S1144, Paris, France
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France
| | - Michel Vidal
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France
- Université Paris Cité, Faculté de Pharmacie de Paris, UMR8038 CNRS CiTCoM, U1268 INSERM, CARPEM, Paris, France
| | - Nora Kramkimel
- Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
| | - Sarah Guegan
- Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
| | - Selim Aractingi
- Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
| | - Olivier Huillard
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
| | - Jérôme Alexandre
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
- Université Paris Cité, INSERM, Centre de Recherche des Cordeliers, Équipe labélisée Ligue Contre le Cancer, CNRS SNC 5096, Sorbonne Université, Paris, France
| | - Marie Wislez
- Department of Pneumology, Cochin University Hospital, AP-HP, Paris, France
| | - François Goldwasser
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
- Université Paris Cité, Faculté de Médecine, INSERM, U1016, Institut Cochin, Paris, France
| | - Benoit Blanchet
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France
- Université Paris Cité, Faculté de Pharmacie de Paris, UMR8038 CNRS CiTCoM, U1268 INSERM, CARPEM, Paris, France
| |
Collapse
|
3
|
Puszkiel A, Bousquet G, Stanke-Labesque F, Stocco J, Decq P, Chevillard L, Goutagny S, Declèves X. A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations. Pharm Res 2023; 40:2687-2697. [PMID: 37821769 DOI: 10.1007/s11095-023-03614-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 09/26/2023] [Indexed: 10/13/2023]
Abstract
BACKGROUND Dosing regimens of trastuzumab administered by intracerebroventricular (icv) route to patients with HER2-positive brain localizations remain empirical. The objectives of this study were to describe pharmacokinetics (PK) of trastuzumab in human plasma and cerebrospinal fluid (CSF) after simultaneous icv and intravenous (iv) administration using a minimal physiologically-based pharmacokinetic model (mPBPK) and to perform simulations of alternative dosing regimens to achieve therapeutic concentrations in CSF. METHODS Plasma and CSF PK data were collected in two patients with HER2-positive brain localizations. A mPBPK model for mAbs consisting of four compartments (tight and leaky tissues, plasma and lymph) was enriched by an additional compartment for ventricular CSF. The comparison between observed and model-predicted concentrations was evaluated using prediction error (PE). RESULTS The developed mPBPK model described plasma and CSF trastuzumab concentrations reasonably well with mean PE for plasma and CSF data of 41.8% [interquartile range, IQR = -9.48; 40.6] and 18.3% [-36.7; 60.6], respectively, for patient 1 and 11.4% [-10.8; 28.7] and 22.5% [-27.7; 77.9], respectively, for patient 2. Trastuzumab showed fast clearance from CSF to plasma with Cmin,ss of 0.56 and 0.85 mg/L for 100 and 150 mg q1wk, respectively. Repeated dosing of 100 and 150 mg q3day resulted in Cmin,ss of 10.3 and 15.4 mg/L, respectively. Trastuzumab CSF target concentrations are achieved rapidly and maintained above 60 mg/L from 7 days after a continuous perfusion at 1.0 mg/h. CONCLUSION Continuous icv infusion of trastuzumab at 1.0 mg/h could be an alternative dosing regimen to rapidly achieve intraventricular CSF therapeutic concentrations.
Collapse
Affiliation(s)
- Alicja Puszkiel
- Université Paris Cité, Inserm UMRS1144, Paris, France
- Laboratory of Pharmacology and Toxicology, Cochin University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Guilhem Bousquet
- Oncology Department, Avicenne Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
- Université Paris Cité, Inserm UMR_S942 MASCOT, Paris, France
- Université Sorbonne Paris Nord, Villetaneuse, France
| | - Françoise Stanke-Labesque
- Laboratory of Pharmacology, Toxicology and Pharmacogenetics, Grenoble-Alpes University Hospital, 38043, Grenoble, France
- Université Grenoble Alpes, HP2 INSERM U1300, Grenoble, France
| | - Jeanick Stocco
- Department of Pharmacy, Beaujon Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Philippe Decq
- Department of Neurosurgery, Beaujon University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | | | - Stéphane Goutagny
- Université Paris Cité, Inserm UMRS1144, Paris, France
- Department of Neurosurgery, Beaujon University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Xavier Declèves
- Université Paris Cité, Inserm UMRS1144, Paris, France.
- Laboratory of Pharmacology and Toxicology, Cochin University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
| |
Collapse
|
4
|
Shawahna R, Saba'aneh H, Daraghmeh A, Qassarwi Y, Franco V, Declèves X. Solubility of lamotrigine in age-specific biorelevant media that simulated the fasted- and fed-conditions of the gastric and intestinal environments in pediatrics and adults: implications for traditional, re-formulated, modified, and new oral formulations. BMC Biotechnol 2023; 23:36. [PMID: 37684623 PMCID: PMC10492362 DOI: 10.1186/s12896-023-00809-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Accepted: 08/29/2023] [Indexed: 09/10/2023] Open
Abstract
BACKGROUND Lamotrigine is an effective antiseizure medication that can be used in the management of focal and generalized epilepsies in pediatric patients. This study was conducted to quantify and compare the solubility of lamotrigine in age-specific biorelevant media that simulated the fasted and fed conditions of the gastric and intestinal environments in pediatrics and adults. Another aim was to predict how traditional, re-formulated, modified, and new oral formulations would behave in the gastric and intestinal environments across different age groups. METHODS Solubility studies of lamotrigine were conducted in 16 different age-specific biorelevant media over the pH range and temperature specified by the current biopharmaceutical classification system-based criteria. The age-specific biorelevant media simulated the environments in the stomach and proximal gastrointestinal tract in both fasted and fed conditions of adults and pediatric sub-populations. The solubility of lamotrigine was determined using a pre-validated HPLC-UV method. RESULTS Lamotrigine showed low solubility in the 16 age-specific biorelevant media as indicated by a dose number of > 1. There were significant age-specific variabilities in the solubility of lamotrigine in the different age-specific biorelevant media. Pediatric/adult solubility ratios of lamotrigine fell outside the 80-125% range in 6 (50.0%) and were borderline in 3 (25.0%) out of the 12 compared media. These ratios indicated that the solubility of lamotrigine showed considerable differences in 9 out of the 12 (75.0%) of the compared media. CONCLUSION Future studies are still needed to generate more pediatric biopharmaceutical data to help understand the performances of oral dosage forms in pediatric sub-populations.
Collapse
Affiliation(s)
- Ramzi Shawahna
- Department of Physiology, Pharmacology and Toxicology, Faculty of Medicine and Health Sciences, An-Najah National University, New Campus, Building: 19, Office: 1340, P.O. Box 7, Nablus, Palestine.
- Clinical Research Center, An-Najah National University Hospital, Nablus, 44839, Palestine.
| | - Hala Saba'aneh
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
| | - Amal Daraghmeh
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
| | - Yara Qassarwi
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
| | - Valentina Franco
- Section of Translational Neurovascular Research, IRCCS Mondino Foundation, Via Mondino 2, Pavia, 27100, Italy
- Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, 27100, Italy
| | - Xavier Declèves
- Biologie du Médicament-Toxicologie, AP-HP, Hôpital Cochin, 27 rue du Faubourg St. Jacques, Paris, 75679, France
- Faculty of Health, Université Paris Cité, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, 75006, France
| |
Collapse
|
5
|
Pasquiers B, Benamara S, Felices M, Ternant D, Declèves X, Puszkiel A. Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab. Pharmaceutics 2023; 15:2129. [PMID: 37631343 PMCID: PMC10459442 DOI: 10.3390/pharmaceutics15082129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 08/03/2023] [Accepted: 08/08/2023] [Indexed: 08/27/2023] Open
Abstract
Interspecies translation of monoclonal antibodies (mAbs) pharmacokinetics (PK) in presence of target-mediated drug disposition (TMDD) is particularly challenging. Incorporation of TMDD in physiologically based PK (PBPK) modeling is recent and needs to be consolidated and generalized to provide better prediction of TMDD regarding inter-species translation during preclinical and clinical development steps of mAbs. The objective of this study was to develop a generic PBPK translational approach for mAbs using the open-source software (PK-Sim® and Mobi®). The translation of bevacizumab based on data in non-human primates (NHP), healthy volunteers (HV), and cancer patients was used as a case example for model demonstration purpose. A PBPK model for bevacizumab concentration-time data was developed using data from literature and the Open Systems Pharmacology (OSP) Suite version 10. PK-sim® was used to build the linear part of bevacizumab PK (mainly FcRn-mediated), whereas MoBi® was used to develop the target-mediated part. The model was first developed for NHP and used for a priori PK prediction in HV. Then, the refined model obtained in HV was used for a priori prediction in cancer patients. A priori predictions were within 2-fold prediction error (predicted/observed) for both area under the concentration-time curve (AUC) and maximum concentration (Cmax) and all the predicted concentrations were within 2-fold average fold error (AFE) and average absolute fold error (AAFE). Sensitivity analysis showed that FcRn-mediated distribution and elimination processes must be accounted for at all mAb concentration levels, whereas the lower the mAb concentration, the more significant the target-mediated elimination. This project is the first step to generalize the full PBPK translational approach in Model-Informed Drug Development (MIDD) of mAbs using OSP Suite.
Collapse
Affiliation(s)
- Blaise Pasquiers
- Inserm UMR-S1144, Faculty of Pharmacy, Université Paris Cité, 75006 Paris, France (A.P.)
- PhinC Development, 91300 Massy, France
| | | | | | - David Ternant
- Faculty of Medicine, Université de Tours, EA 4245 T2I, 37032 Tours, France
- Service de Pharmacologie Médicale, CHRU de Tours, 37000 Tours, France
| | - Xavier Declèves
- Inserm UMR-S1144, Faculty of Pharmacy, Université Paris Cité, 75006 Paris, France (A.P.)
- Biologie du Médicament—Toxicologie, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, 75014 Paris, France
| | - Alicja Puszkiel
- Inserm UMR-S1144, Faculty of Pharmacy, Université Paris Cité, 75006 Paris, France (A.P.)
- Biologie du Médicament—Toxicologie, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, 75014 Paris, France
| |
Collapse
|
6
|
Abstract
Although levothyroxine (LT4) is a widely prescribed drug, more than 30% of LT4-treated patients fail to achieve the recommended serum level of thyrotropin with a body weight-based dose of LT4. An LT4 absorption test (LT4AT) is part of the workup for confirming normal LT4 absorption or diagnosing malabsorption. We searched PubMed with the terms levothyrox*, L-T4, LT4, TT4, FT4, FT3, TT3, test, loading, uptake, absorp*, "absorb*, bioavailab*, bioequiv* malabsorb*, and pseudomalabsorb*. A total of 43 full-text publications were analyzed. The published procedures for LT4AT differ markedly in the test dose, formulation, test duration, frequency of blood collection, analyte (total thyroxine [TT4] or free thyroxine [FT4]), metric (absolute or relative peak or increment, or area under the curve) and the threshold for normal absorption. In a standardized LT4AT for routine use, the physician could advise the patient to not consume food, beverages, or medications the morning of the test; administer 1000 µg of LT4 in the patient's usual formulation as the test dose; ensure that the patient is supervised throughout the LT4AT; perform a 4-hour test, with hourly blood samples; assay FT4; and consider that normal LT4 absorption corresponds to an FT4 increment of more than 0.40 ng/dL (5.14 pmol/L) or a TT4 increment of more than 6 μg/dL (77.23 nmol/L) for a test dose of at least 300 µg, or a percentage TT4 absorption of more than 60%. If the test indicates abnormal LT4 absorption, the physician can increase the LT4 dose, change the formulation or administration route, and/or refer the patient to a gastroenterologist.
Collapse
Affiliation(s)
- Philippe Caron
- Service d'Endocrinologie, Maladies Métaboliques et Nutrition, Pôle Cardio-Vasculaire et Métabolique, Hôpital Larrey, CHU de Toulouse, Toulouse F-31059, France
| | - Xavier Declèves
- Service de Biologie du Médicament-Toxicologie, Hôpital Cochin, AP-HP, Paris F-75006, France
- INSERM UMR-S1144, Université Paris Cité, Paris F-75006, France
| |
Collapse
|
7
|
Darnaud L, Delage C, Daali Y, Trouvin AP, Perrot S, Khoudour N, Merise N, Labat L, Etain B, Bellivier F, Lloret-Linares C, Bloch V, Curis E, Declèves X. Phenotyping Indices of CYP450 and P-Glycoprotein in Human Volunteers and in Patients Treated with Painkillers or Psychotropic Drugs. Pharmaceutics 2023; 15:pharmaceutics15030979. [PMID: 36986840 PMCID: PMC10054647 DOI: 10.3390/pharmaceutics15030979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 03/02/2023] [Accepted: 03/15/2023] [Indexed: 03/30/2023] Open
Abstract
Drug-metabolizing enzymes and drug transporters are key determinants of drug pharmacokinetics and response. The cocktail-based cytochrome P450 (CYP) and drug transporter phenotyping approach consists in the administration of multiple CYP or transporter-specific probe drugs to determine their activities simultaneously. Several drug cocktails have been developed over the past two decades in order to assess CYP450 activity in human subjects. However, phenotyping indices were mostly established for healthy volunteers. In this study, we first performed a literature review of 27 clinical pharmacokinetic studies using drug phenotypic cocktails in order to determine 95%,95% tolerance intervals of phenotyping indices in healthy volunteers. Then, we applied these phenotypic indices to 46 phenotypic assessments processed in patients having therapeutic issues when treated with painkillers or psychotropic drugs. Patients were given the complete phenotypic cocktail in order to explore the phenotypic activity of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A, and P-glycoprotein (P-gp). P-gp activity was evaluated by determining AUC0-6h for plasma concentrations over time of fexofenadine, a well-known substrate of P-gp. CYP metabolic activities were assessed by measuring the CYP-specific metabolite/parent drug probe plasma concentrations, yielding single-point metabolic ratios at 2 h, 3 h, and 6 h or AUC0-6h ratio after oral administration of the cocktail. The amplitude of phenotyping indices observed in our patients was much wider than those observed in the literature for healthy volunteers. Our study helps define the range of phenotyping indices with "normal" activities in human volunteers and allows classification of patients for further clinical studies regarding CYP and P-gp activities.
Collapse
Affiliation(s)
- Léa Darnaud
- Biologie du Médicament-Toxicologie, AP-HP, Hôpital Cochin, 27 rue du Faubourg St. Jacques, 75679 Paris, France
| | - Clément Delage
- Faculty of Health, Université Paris Cité, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France
- Service de Pharmacie, Hôpital Lariboisière-Fernand Widal, AP-HP, 75010 Paris, France
| | - Youssef Daali
- Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland
| | | | - Serge Perrot
- Centre de la Douleur, AP-HP, Hôpital Cochin, 75679 Paris, France
| | - Nihel Khoudour
- Biologie du Médicament-Toxicologie, AP-HP, Hôpital Cochin, 27 rue du Faubourg St. Jacques, 75679 Paris, France
| | - Nadia Merise
- Biologie du Médicament-Toxicologie, AP-HP, Hôpital Cochin, 27 rue du Faubourg St. Jacques, 75679 Paris, France
| | - Laurence Labat
- Faculty of Health, Université Paris Cité, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France
- Laboratoire de Toxicologie, Hôpital Lariboisière, AP-HP, 75010 Paris, France
| | - Bruno Etain
- Faculty of Health, Université Paris Cité, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France
- Département de Psychiatrie et de Médecine Addictologique, Hôpital GHU Lariboisière-Fernand Widal, AP-HP, 75010 Paris, France
| | - Frank Bellivier
- Faculty of Health, Université Paris Cité, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France
- Département de Psychiatrie et de Médecine Addictologique, Hôpital GHU Lariboisière-Fernand Widal, AP-HP, 75010 Paris, France
| | | | - Vanessa Bloch
- Faculty of Health, Université Paris Cité, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France
- Service de Pharmacie, Hôpital Lariboisière-Fernand Widal, AP-HP, 75010 Paris, France
| | - Emmanuel Curis
- Faculté de Pharmacie de Paris, Université Paris Cité, UR 7537 BioSTM, 75006 Paris, France
- Laboratoire d'hématologie, Hôpital Lariboisière, AP-HP, 75010 Paris, France
| | - Xavier Declèves
- Biologie du Médicament-Toxicologie, AP-HP, Hôpital Cochin, 27 rue du Faubourg St. Jacques, 75679 Paris, France
- Faculty of Health, Université Paris Cité, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France
| |
Collapse
|
8
|
Balakirouchenane D, Vasseur A, Bonnet-Serrano F, Choi M, Khoudour N, Puszkiel A, Groussin L, Vidal M, Declèves X, Bertherat J, Blanchet B. LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing's Syndrome. J Pharm Biomed Anal 2023; 228:115316. [PMID: 36868030 DOI: 10.1016/j.jpba.2023.115316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 02/13/2023] [Accepted: 02/23/2023] [Indexed: 03/05/2023]
Abstract
Steroidogenesis inhibitors such as metyrapone (MTP) and osilodrostat (ODT) have a key role in the medical treatment of endogenous Cushing's Syndrome (ECS). Both drugs are characterized by a high inter-individual variability of response and require a dose-titration period to achieve optimal control of cortisol excess. However, PK/PD data remain scarce for both molecules and a pharmacokinetically guided approach could help reaching eucortisolism more rapidly. We aimed to develop and validate a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of ODT and MTP in human plasma. After addition of isotopically labeled internal standard (IS), plasma pretreatment consisted in protein precipitation with acetonitrile including 1% formic acid (v/v). Chromatographic separation was performed on Kinetex® HILIC (4.6 × 50 mm; 2.6 µm) analytical column with an isocratic elution during the 2.0-min run time. The method was linear from 0.5 to 250 ng/mL for ODT and from 2.5 to 1250 ng/mL for MTP. Intra- and inter-assay precisions were < 7.2%, with an accuracy ranging from 95.9% to 114.9%. The IS-normalized matrix effect ranged from 106.0% to 123.0% (ODT) and from 107.0% to 123.0% (MTP) and the range of the IS-normalized extraction recovery was 84.0-101.0% for ODT and 87.0-101.0% for MTP. The LC-MS/MS method was successfully applied in patients' plasma samples (n = 36), trough concentration of ODT and MTP ranged from 2.7 ng/mL to 8.2 ng/mL and from 10.8 ng/mL to 27.8 ng/mL, respectively. Incurred sample reanalysis exhibits less than 14% difference between the first and the second analysis for both drugs. This accurate and precise method, meeting all validation criteria, can therefore be used for plasma drug monitoring of ODT and MTP within the dose-titration period.
Collapse
Affiliation(s)
- David Balakirouchenane
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; Université Paris Cité, UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, CARPEM, 75006 Paris, France.
| | - Axelle Vasseur
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France
| | - Fidéline Bonnet-Serrano
- Hormonal Biology Laboratory, Cochin Hospital, AP-HP, 75014 Paris, France; Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR8104, 75006 Paris, France
| | - Minna Choi
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France
| | - Nihel Khoudour
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France
| | - Alicja Puszkiel
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; Université Paris Cité, INSERM UMR-S1144, Faculty of Pharmacy, 75006 Paris, France
| | - Lionel Groussin
- Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR8104, 75006 Paris, France; Department of Endocrinology, Cochin Hospital, AP-HP, 75014 Paris, France
| | - Michel Vidal
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; Université Paris Cité, UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, CARPEM, 75006 Paris, France
| | - Xavier Declèves
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; Université Paris Cité, INSERM UMR-S1144, Faculty of Pharmacy, 75006 Paris, France
| | - Jérôme Bertherat
- Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR8104, 75006 Paris, France; Department of Endocrinology, Cochin Hospital, AP-HP, 75014 Paris, France
| | - Benoit Blanchet
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; Université Paris Cité, UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, CARPEM, 75006 Paris, France
| |
Collapse
|
9
|
Derippe T, Fouliard S, Marchiq I, Dupouy S, Almena-Carrasco M, Geronimi J, Declèves X, Chenel M, Mager DE. Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia. Cancer Res Commun 2022; 2:1532-1544. [PMID: 36970053 PMCID: PMC10036133 DOI: 10.1158/2767-9764.crc-22-0176] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 09/06/2022] [Accepted: 11/03/2022] [Indexed: 06/18/2023]
Abstract
UNLABELLED Chimeric antigen receptor (CAR)-T cell therapies have shown tremendous results against various hematologic cancers. Prior to cell infusion, a host preconditioning regimen is required to achieve lymphodepletion and improve CAR-T cell pharmacokinetic exposure, leading to greater chances of therapeutic success. To better understand and quantify the impact of the preconditioning regimen, we built a population-based mechanistic pharmacokinetic-pharmacodynamic model describing the complex interplay between lymphodepletion, host immune system, homeostatic cytokines, and pharmacokinetics of UCART19, an allogeneic product developed against CD19+ B cells. Data were collected from a phase I clinical trial in adult relapsed/refractory B-cell acute lymphoblastic leukemia and revealed three different UCART19 temporal patterns: (i) expansion and persistence, (ii) transient expansion with subsequent rapid decline, and (iii) absence of observed expansion. On the basis of translational assumptions, the final model was able to capture this variability through the incorporation of IL-7 kinetics, which are thought to be increased owing to lymphodepletion, and through an elimination of UCART19 by host T cells, which is specific to the allogeneic context. Simulations from the final model recapitulated UCART19 expansion rates in the clinical trial, confirmed the need for alemtuzumab to observe UCART19 expansion (along with fludarabine cyclophosphamide), quantified the importance of allogeneic elimination, and suggested a high impact of multipotent memory T-cell subpopulations on UCART19 expansion and persistence. In addition to supporting the role of host cytokines and lymphocytes in CAR-T cell therapy, such a model could help optimizing the preconditioning regimens in future clinical trials. SIGNIFICANCE A mathematical mechanistic pharmacokinetic/pharmacodynamic model supports and captures quantitatively the beneficial impact of lymphodepleting patients before the infusion of an allogeneic CAR-T cell product. Mediation through IL-7 increase and host T lymphocytes decrease is underlined, and the model can be further used to optimize CAR-T cell therapies lymphodepletion regimen.
Collapse
Affiliation(s)
- Thibaud Derippe
- Institut de Recherches Internationales Servier, Suresnes, France
- Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York
- Université de Paris, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, France
| | - Sylvain Fouliard
- Institut de Recherches Internationales Servier, Suresnes, France
| | - Ibtissam Marchiq
- Institut de Recherches Internationales Servier, Suresnes, France
| | - Sandra Dupouy
- Institut de Recherches Internationales Servier, Suresnes, France
| | | | - Julia Geronimi
- Institut de Recherches Internationales Servier, Suresnes, France
| | - Xavier Declèves
- Université de Paris, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, France
| | - Marylore Chenel
- Institut de Recherches Internationales Servier, Suresnes, France
| | - Donald E. Mager
- Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York
| |
Collapse
|
10
|
Pasquiers B, Benamara S, Felices M, Nguyen L, Declèves X. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection. Int J Mol Sci 2022; 23:12754. [PMID: 36361546 PMCID: PMC9657028 DOI: 10.3390/ijms232112754] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2022] [Revised: 10/18/2022] [Accepted: 10/19/2022] [Indexed: 08/27/2023] Open
Abstract
The interest in therapeutic monoclonal antibodies (mAbs) has continuously growing in several diseases. However, their pharmacokinetics (PK) is complex due to their target-mediated drug disposition (TMDD) profiles which can induce a non-linear PK. This point is particularly challenging during the pre-clinical and translational development of a new mAb. This article reviews and describes the existing PK modeling approaches used to translate the mAbs PK from animal to human for intravenous (IV) and subcutaneous (SC) administration routes. Several approaches are presented, from the most empirical models to full physiologically based pharmacokinetic (PBPK) models, with a focus on the population PK methods (compartmental and minimal PBPK models). They include the translational approaches for the linear part of the PK and the TMDD mechanism of mAbs. The objective of this article is to provide an up-to-date overview and future perspectives of the translational PK approaches for mAbs during a model-informed drug development (MIDD), since the field of PK modeling has gained recently significant interest for guiding mAbs drug development.
Collapse
Affiliation(s)
- Blaise Pasquiers
- PhinC Development, 91300 Massy, France
- Université Paris Cité, Inserm UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France
| | | | | | | | - Xavier Declèves
- Université Paris Cité, Inserm UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France
| |
Collapse
|
11
|
Choublier N, Taghi M, Menet MC, Le Gall M, Bruce J, Chafey P, Guillonneau F, Moreau A, Denizot C, Parmentier Y, Nakib S, Borderie D, Bouzinba-Segard H, Couraud PO, Bourdoulous S, Declèves X. Exposure of human cerebral microvascular endothelial cells hCMEC/D3 to laminar shear stress induces vascular protective responses. Fluids Barriers CNS 2022; 19:41. [PMID: 35658915 PMCID: PMC9164338 DOI: 10.1186/s12987-022-00344-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 05/23/2022] [Indexed: 01/01/2023] Open
Abstract
Endothelial cells (ECs) are constantly submitted in vivo to hemodynamical forces derived from the blood circulation, including shear stress (SS). ECs are able to detect SS and consequently adapt their phenotype, thus affecting many endothelial functions. If a plethora of shear stress-regulated molecular networks have been described in peripheral ECs, less is known about the molecular responses of microvascular brain ECs which constitute the blood-brain barrier (BBB). In this work, we investigated the response of human cerebral microvascular ECs to laminar physiological shear stress using the well characterized hCMEC/D3 cell line. Interestingly, we showed that hCMEC/D3 cells responded to shear stress by aligning perpendicularly to the flow direction, contrary to peripheral endothelial cells which aligned in the flow direction. Whole proteomic profiles were compared between hCMEC/D3 cells cultured either in static condition or under 5 or 10 dyn.cm-2 SS for 3 days. 3592 proteins were identified and expression levels were significantly affected for 3% of them upon both SS conditions. Pathway analyses were performed which revealed that most proteins overexpressed by SS refer to the antioxidant defense, probably mediated by activation of the NRF2 transcriptional factor. Regarding down-regulated proteins, most of them participate to the pro-inflammatory response, cell motility and proliferation. These findings confirm the induction of EC quiescence by laminar physiological SS and reveal a strong protective effect of SS on hCMEC/D3 cells, suggesting a similar effect on the BBB. Our results also showed that SS did not significantly increase expression levels nor did it affect the localization of junctional proteins and did not afect either the functional activity of several ABC transporters (P-glycoprotein and MRPs). This work provides new insights on the response of microvascular brain ECs to SS and on the importance of SS for optimizing in vitro BBB models.
Collapse
Affiliation(s)
- Nina Choublier
- INSERM, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, 75006, Paris, France.
| | - Meryam Taghi
- INSERM, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, 75006, Paris, France
| | - Marie-Claude Menet
- Institut de Chimie Physique, CNRS, Université Paris-Saclay, 91405, Orsay, France
| | - Morgane Le Gall
- 3P5 Proteom'IC Facility, Institut Cochin, INSERM, CNRS, Université de Paris, F-75014, Paris, France
| | - Johanna Bruce
- 3P5 Proteom'IC Facility, Institut Cochin, INSERM, CNRS, Université de Paris, F-75014, Paris, France
| | - Philippe Chafey
- 3P5 Proteom'IC Facility, Institut Cochin, INSERM, CNRS, Université de Paris, F-75014, Paris, France
| | - François Guillonneau
- 3P5 Proteom'IC Facility, Institut Cochin, INSERM, CNRS, Université de Paris, F-75014, Paris, France
| | | | | | | | - Samir Nakib
- Service de Biochimie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France
| | - Didier Borderie
- Service de Biochimie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France
| | - Haniaa Bouzinba-Segard
- CNRS, INSERM, Institut Cochin, Inserm, CNRS, Université Paris Cité, 75014, Paris, France
| | - Pierre-Olivier Couraud
- CNRS, INSERM, Institut Cochin, Inserm, CNRS, Université Paris Cité, 75014, Paris, France
| | - Sandrine Bourdoulous
- CNRS, INSERM, Institut Cochin, Inserm, CNRS, Université Paris Cité, 75014, Paris, France
| | - Xavier Declèves
- INSERM, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, 75006, Paris, France.
- Biologie du Médicament Et Toxicologie, AP-HP, Hôpital Cochin, 75014, Paris, France.
| |
Collapse
|
12
|
Puszkiel A, Malissin I, Cisternino S, Pallet N, Declèves X, Mégarbane B. Massive tramadol ingestion resulting in fatal brain injury - a pharmacokinetic study with discussion on the involved mechanisms of toxicity. Clin Toxicol (Phila) 2022; 60:1059-1062. [PMID: 35506822 DOI: 10.1080/15563650.2022.2071286] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Tramadol-attributed toxicity may involve opioid-like, serotoninergic, and noradrenergic mechanisms. We investigated the mechanisms of toxicity in a massive tramadol ingestion case by examining serial clinical, imaging, electroencephalography, pharmacokinetics, and genotyping data. CASE REPORT A 32-year-old female who presumably ingested 9000 mg sustained-release tramadol was found comatose without hypoglycemia, bradypnea, hypotension, marked hypoxemia or seizures. She developed eyelid myoclonus and non-reactive mydriasis. Electroencephalogram showed non-reactive encephalopathy. MRI showed extensive brain injury. Despite supportive care and ventricular derivation, brain death occurred on day 12. METHODS Plasma concentrations of tramadol and metabolites were measured using a liquid chromatography-tandem mass spectrometry assay. Genotyping for the presence of metabolizing cytochrome P450 (CYP) gene polymorphisms was performed. RESULTS Plasma concentrations of tramadol and metabolites were extremely high (∼70-fold the therapeutic concentrations) and slowly decreased during the first ∼146 h post-admission, possibly due to prolonged gastrointestinal absorption. Elimination half-lives were 2-3-fold longer than usual values. The patient was an intermediate CYP2D6 metabolizer with decreased CYP3A4 and CYP2B6 activities. Clinical and electroencephalographic data did not support the hypotheses of opioid or serotoninergic toxicity nor prolonged/repeated seizures. Based on serial imaging showing progressive extension of ischemic edema in the context of prolonged high plasma concentrations, we hypothesized a cerebral vasospasm as mechanism of injury. CONCLUSION Massive tramadol ingestion with prolonged high plasma concentrations can result in severe brain injury, possibly involving vasospasm.
Collapse
Affiliation(s)
- Alicja Puszkiel
- Biologie du Médicament, Hôpital Cochin, AP-HP, Paris, France.,Université de Paris, Inserm UMRS, Paris, France
| | - Isabelle Malissin
- Université de Paris, Inserm UMRS, Paris, France.,Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Fédération de Toxicologie, AP-HP, Paris, France
| | - Salvatore Cisternino
- Université de Paris, Inserm UMRS, Paris, France.,Pharmacie, AP-HP, Hôpital Necker-Enfants-Malades, Paris, France
| | - Nicolas Pallet
- Service de Biochimie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.,Inserm U1138, Centre de Recherche des Cordeliers, Université de Paris, Paris, France
| | - Xavier Declèves
- Biologie du Médicament, Hôpital Cochin, AP-HP, Paris, France.,Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Fédération de Toxicologie, AP-HP, Paris, France
| | - Bruno Mégarbane
- Université de Paris, Inserm UMRS, Paris, France.,Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Fédération de Toxicologie, AP-HP, Paris, France
| |
Collapse
|
13
|
Smirnova M, Goracci L, Cruciani G, Federici L, Declèves X, Chapy H, Cisternino S. Pharmacophore-Based Discovery of Substrates of a Novel Drug/Proton-Antiporter in the Human Brain Endothelial hCMEC/D3 Cell Line. Pharmaceutics 2022; 14:pharmaceutics14020255. [PMID: 35213988 PMCID: PMC8875908 DOI: 10.3390/pharmaceutics14020255] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 01/14/2022] [Accepted: 01/18/2022] [Indexed: 11/16/2022] Open
Abstract
A drug/proton-antiporter, whose the molecular structure is still unknown, was previously evidenced at the blood-brain barrier (BBB) by functional experiments. The computational method could help in the identification of substrates of this solute carrier (SLC) transporter. Two pharmacophore models for substrates of this transporter using the FLAPpharm approach were developed. The trans-stimulation potency of 40 selected compounds for already known specific substrates ([3H]-clonidine) were determined and compared in the human brain endothelial cell line hCMEC/D3. Results. The two pharmacophore models obtained were used as templates to screen xenobiotic and endogenous compounds from four databases (e.g., Specs), and 45 hypothetical new candidates were tested to determine their substrate capacity. Psychoactive drugs such as antidepressants (e.g., imipramine, desipramine), antipsychotics/neuroleptics such as phenothiazine derivatives (chlorpromazine), sedatives anti-histamine-H1 drugs (promazine, promethazine, triprolidine, pheniramine), opiates/opioids (e.g., hydrocodone), trihexyphenidyl and sibutramine were correctly predicted as proton-antiporter substrates. The best performing pharmacophore model for the proton-antiporter substrates appeared as a good predictor of known substrates and allowed the identification of new substrate compounds. This model marks a new step in the characterization of this drug/proton-antiporter and will be of great use in uncovering its substrates and designing chemical entities with an improved influx capability to cross the BBB.
Collapse
Affiliation(s)
- Maria Smirnova
- Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (M.S.); (L.F.); (X.D.); (H.C.)
| | - Laura Goracci
- Biology and Biotechnology, Department of Chemistry, University of Perugia, 06123 Perugia, Italy; (L.G.); (G.C.)
| | - Gabriele Cruciani
- Biology and Biotechnology, Department of Chemistry, University of Perugia, 06123 Perugia, Italy; (L.G.); (G.C.)
| | - Laetitia Federici
- Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (M.S.); (L.F.); (X.D.); (H.C.)
| | - Xavier Declèves
- Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (M.S.); (L.F.); (X.D.); (H.C.)
- Biologie du Médicament et Toxicologie, AP-HP, Hôpital Cochin, 75014 Paris, France
| | - Hélène Chapy
- Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (M.S.); (L.F.); (X.D.); (H.C.)
| | - Salvatore Cisternino
- Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (M.S.); (L.F.); (X.D.); (H.C.)
- Service Pharmacie, AP-HP, Hôpital Necker-Enfants Malades, 75015 Paris, France
- Correspondence: ; Tel.: +33-1-44-495-191
| |
Collapse
|
14
|
Gilbert A, Elorza-Vidal X, Rancillac A, Chagnot A, Yetim M, Hingot V, Deffieux T, Boulay AC, Alvear-Perez R, Cisternino S, Martin S, Taïb S, Gelot A, Mignon V, Favier M, Brunet I, Declèves X, Tanter M, Estevez R, Vivien D, Saubaméa B, Cohen-Salmon M. Megalencephalic leukoencephalopathy with subcortical cysts is a developmental disorder of the gliovascular unit. eLife 2021; 10:71379. [PMID: 34723793 PMCID: PMC8598235 DOI: 10.7554/elife.71379] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Accepted: 10/27/2021] [Indexed: 12/20/2022] Open
Abstract
Absence of the astrocyte-specific membrane protein MLC1 is responsible for megalencephalic leukoencephalopathy with subcortical cysts (MLC), a rare type of leukodystrophy characterized by early-onset macrocephaly and progressive white matter vacuolation that lead to ataxia, spasticity, and cognitive decline. During postnatal development (from P5 to P15 in the mouse), MLC1 forms a membrane complex with GlialCAM (another astrocytic transmembrane protein) at the junctions between perivascular astrocytic processes. Perivascular astrocytic processes along with blood vessels form the gliovascular unit. It was not previously known how MLC1 influences the physiology of the gliovascular unit. Here, using the Mlc1 knock-out mouse model of MLC, we demonstrated that MLC1 controls the postnatal development and organization of perivascular astrocytic processes, vascular smooth muscle cell contractility, neurovascular coupling, and intraparenchymal interstitial fluid clearance. Our data suggest that MLC is a developmental disorder of the gliovascular unit, and perivascular astrocytic processes and vascular smooth muscle cell maturation defects are primary events in the pathogenesis of MLC and therapeutic targets for this disease.
Collapse
Affiliation(s)
- Alice Gilbert
- Physiology and Physiopathology of the Gliovascular Unit Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, CNRS Research in Biology (CIRB), College de France, CNRS, Paris, France.,École doctorale Cerveau Cognition Comportement "ED3C" N°158, Pierre and Marie Curie University, Paris, France
| | - Xabier Elorza-Vidal
- Physiology and Physiopathology of the Gliovascular Unit Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, CNRS Research in Biology (CIRB), College de France, CNRS, Paris, France
| | - Armelle Rancillac
- Neuroglial Interactions in Cerebral Physiopathology Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, Labex Memolife, Université PSL, Paris, France
| | - Audrey Chagnot
- Normandie University, UNICAEN, INSERM, GIP Cyceron, Institut Blood and Brain, Physiopathology and Imaging of Neurological Disorders, Caen, France
| | - Mervé Yetim
- Normandie University, UNICAEN, INSERM, GIP Cyceron, Institut Blood and Brain, Physiopathology and Imaging of Neurological Disorders, Caen, France
| | - Vincent Hingot
- Physics for Medicine Paris, ESPCI Paris, PSL University, Paris, France
| | - Thomas Deffieux
- Physics for Medicine Paris, ESPCI Paris, PSL University, Paris, France
| | - Anne-Cécile Boulay
- Physiology and Physiopathology of the Gliovascular Unit Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, CNRS Research in Biology (CIRB), College de France, CNRS, Paris, France
| | - Rodrigo Alvear-Perez
- Physiology and Physiopathology of the Gliovascular Unit Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, CNRS Research in Biology (CIRB), College de France, CNRS, Paris, France
| | | | - Sabrina Martin
- Molecular Control of the Neurovascular Development Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, Labex Memolife, Université PSL, Paris, France
| | - Sonia Taïb
- Molecular Control of the Neurovascular Development Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, Labex Memolife, Université PSL, Paris, France
| | - Aontoinette Gelot
- Service d'anatomie et cytologie pathologie de l'hôpital Armand Trousseau, Paris, France
| | - Virginie Mignon
- Cellular and Molecular Imaging Facility, US25 INSERM, UMS3612 CNRS, Faculty of Pharmacy, University of Paris, Paris, France
| | | | - Isabelle Brunet
- Molecular Control of the Neurovascular Development Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, Labex Memolife, Université PSL, Paris, France
| | - Xavier Declèves
- Université de Paris, Faculté de Santé, Paris, France.,Biologie du médicament et toxicologie, Assistance Publique - hôpitaux de Paris, APHP, Hôpital Cochin, Paris, France
| | - Mickael Tanter
- Physics for Medicine Paris, ESPCI Paris, PSL University, Paris, France
| | - Raul Estevez
- Unitat de Fisiología, Departament de Ciències Fisiològiques, IDIBELL-Institute of Neurosciences, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.,Centro de Investigación en Red de Enfermedades Raras (CIBERER), Barcelona, Spain
| | - Denis Vivien
- Normandie University, UNICAEN, INSERM, GIP Cyceron, Institut Blood and Brain, Physiopathology and Imaging of Neurological Disorders, Caen, France
| | - Bruno Saubaméa
- Université de Paris, Faculté de Santé, Paris, France.,Cellular and Molecular Imaging Facility, US25 INSERM, UMS3612 CNRS, Faculty of Pharmacy, University of Paris, Paris, France
| | - Martine Cohen-Salmon
- Physiology and Physiopathology of the Gliovascular Unit Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, CNRS Research in Biology (CIRB), College de France, CNRS, Paris, France
| |
Collapse
|
15
|
Mégarbane B, Chevillard L, Khoudour N, Declèves X. Gliclazide disposition in overdose - a case report with pharmacokinetic modeling. Clin Toxicol (Phila) 2021; 60:541-542. [PMID: 34698608 DOI: 10.1080/15563650.2021.1993245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Bruno Mégarbane
- Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology, APHP, Paris, France.,Paris University, Paris, France
| | | | - Nihel Khoudour
- Laboratory of Pharmacology and Toxicology, Cochin Hospital, APHP, Paris, France
| | - Xavier Declèves
- Paris University, Paris, France.,Laboratory of Pharmacology and Toxicology, Cochin Hospital, APHP, Paris, France
| |
Collapse
|
16
|
Bianconi G, Malissin I, Labat L, Khoudour N, Houzé P, Pallet N, Mégarbane B, Declèves X. Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. Clin Toxicol (Phila) 2021; 60:382-385. [PMID: 34287102 DOI: 10.1080/15563650.2021.1955912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Tramadol poisoning rarely causes serotonin toxicity, which mechanisms remain poorly understood. We investigated alterations in tramadol pharmacokinetics in a tramadol-poisoned patient who presented with marked and prolonged serotonin toxicity. CASE REPORT A 21-year-old male self-ingested 750 mg-tramadol, 200 mg-sotalol, 400 mg-propranolol and 6 mg-lorazepam. He was a kidney transplant patient treated with mycophenolate, tacrolimus, prednisone, and paroxetine. He developed transitory cardiovascular failure and prolonged serotonin toxicity requiring sedation, muscle paralysis, and cyproheptadine, with a favorable outcome. METHODS We measured plasma concentrations of tramadol, M1, M2, and M5 using liquid-chromatography-tandem mass spectrometry, calculated elimination half-lives and metabolic ratios of the compounds, and genotyped cytochromes involved in tramadol metabolism. RESULTS Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged. M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal. This metabolic profile in a patient with normal CYP2D6-metabolizer status based on genotyping supports CYP2D6 inhibition by paroxetine and propranolol, two strong mechanism-based inhibitors. Only M2 present in sufficient concentrations up to 48 h could explain the prolonged serotonin toxicity. CONCLUSION Marked and prolonged serotonin toxicity was attributed to increased M2 production due to paroxetine- and propranolol-related CYP2D6 inhibition of tramadol metabolism.
Collapse
Affiliation(s)
| | - Isabelle Malissin
- Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Fédération de Toxicologie de l'AP-HP, Paris, France.,Inserm, UMRS-1144, Université de Paris, Paris, France
| | - Laurence Labat
- Inserm, UMRS-1144, Université de Paris, Paris, France.,Laboratoire de Toxicologie, AP-HP, Hôpital Lariboisière, Paris, France
| | - Nihel Khoudour
- Biologie du Médicament, AP-HP, Hôpital Cochin, Paris, France
| | - Pascal Houzé
- Laboratoire de Toxicologie, AP-HP, Hôpital Lariboisière, Paris, France
| | - Nicolas Pallet
- Service de Biochimie, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.,INSERM U1138, Centre de Recherche des Cordeliers, Université de Paris, Paris, France
| | - Bruno Mégarbane
- Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Fédération de Toxicologie de l'AP-HP, Paris, France.,Inserm, UMRS-1144, Université de Paris, Paris, France
| | - Xavier Declèves
- Biologie du Médicament, AP-HP, Hôpital Cochin, Paris, France.,Inserm, UMRS-1144, Université de Paris, Paris, France
| |
Collapse
|
17
|
Taccola C, Barneoud P, Cartot-Cotton S, Valente D, Schussler N, Saubaméa B, Chasseigneaux S, Cochois V, Mignon V, Curis E, Lochus M, Nicolic S, Dodacki A, Cisternino S, Declèves X, Bourasset F. Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration. Neuropharmacology 2021; 191:108588. [PMID: 33940010 DOI: 10.1016/j.neuropharm.2021.108588] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Revised: 04/10/2021] [Accepted: 04/20/2021] [Indexed: 12/28/2022]
Abstract
The inducible p25 overexpression mouse model recapitulate many hallmark features of Alzheimer's disase including progressive neuronal loss, elevated Aβ, tau pathology, cognitive dysfunction, and impaired synaptic plasticity. We chose p25 mice to evaluate the physical and functional integrity of the blood-brain barrier (BBB) in a context of Tau pathology (pTau) and severe neurodegeneration, at an early (3 weeks ON) and a late (6 weeks ON) stage of the pathology. Using in situ brain perfusion and confocal imaging, we found that the brain vascular surface area and the physical integrity of the BBB were unaltered in p25 mice. However, there was a significant 14% decrease in cerebrovascular volume in 6 weeks ON mice, possibly explained by a significant 27% increase of collagen IV in the basement membrane of brain capillaries. The function of the BBB transporters GLUT1 and LAT1 was evaluated by measuring brain uptake of d-glucose and phenylalanine, respectively. In 6 weeks ON p25 mice, d-glucose brain uptake was significantly reduced by about 17% compared with WT, without any change in the levels of GLUT1 protein or mRNA in brain capillaries. The brain uptake of phenylalanine was not significantly reduced in p25 mice compared with WT. Lack of BBB integrity, impaired BBB d-glucose transport have been observed in several mouse models of AD. In contrast, reduced cerebrovascular volume and an increased basement membrane thickness may be more specifically associated with pTau in mouse models of neurodegeneration.
Collapse
Affiliation(s)
- Camille Taccola
- Pharmacokinetics, Dynamics and Metabolism, Translational Medicine & Early Development, Sanofi, 3 Digue d'Alfortville, 94140, Alfortville, France; INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Pascal Barneoud
- Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, 1 Avenue Pierre Brossolette, 91380, Chilly-Mazarin, France
| | - Sylvaine Cartot-Cotton
- Pharmacokinetics, Dynamics and Metabolism, Translational Medicine & Early Development, Sanofi, 3 Digue d'Alfortville, 94140, Alfortville, France
| | - Delphine Valente
- Drug Metabolism & Pharmacokinetics, Research platform, Sanofi, 3 Digue d'Alfortville, 94140, Alfortville, France
| | - Nathalie Schussler
- Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, 1 Avenue Pierre Brossolette, 91380, Chilly-Mazarin, France
| | - Bruno Saubaméa
- INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Stéphanie Chasseigneaux
- INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Véronique Cochois
- INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Virginie Mignon
- INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Emmanuel Curis
- Laboratoire de biomathématiques, plateau iB(2), EA 7537 « BioSTM », UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France; Service de bioinformatique et statistique médicale, hôpital Saint-Louis, APHP, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Murielle Lochus
- INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Sophie Nicolic
- INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Agnès Dodacki
- INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Salvatore Cisternino
- INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Xavier Declèves
- INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Fanchon Bourasset
- Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive, Université Bourgogne Franche-Comté, 19 rue Ambroise Paré, 25000, Besançon, France.
| |
Collapse
|
18
|
Luo H, Chevillard L, Bellivier F, Mégarbane B, Etain B, Cisternino S, Declèves X. The role of brain barriers in the neurokinetics and pharmacodynamics of lithium. Pharmacol Res 2021; 166:105480. [PMID: 33549730 DOI: 10.1016/j.phrs.2021.105480] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Revised: 01/14/2021] [Accepted: 02/01/2021] [Indexed: 12/14/2022]
Abstract
Lithium (Li) is the most widely used mood stabilizer in treating patients with bipolar disorder. However, more than half of the patients do not or partially respond to Li therapy, despite serum Li concentrations in the serum therapeutic range. The exact mechanisms underlying the pharmacokinetic-pharmacodynamic (PK-PD) relationships of lithium are still poorly understood and alteration in the brain pharmacokinetics of lithium may be one of the mechanisms explaining the variability in the clinical response to Li. Brain barriers such as the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) play a crucial role in controlling blood-to-brain and brain-to-blood exchanges of various molecules including central nervous system (CNS) drugs. Recent in vivo studies by nuclear resonance spectroscopy revealed heterogenous brain distribution of Li in human that were not always correlated with serum concentrations, suggesting regional and variable transport mechanisms of Li through the brain barriers. Moreover, alteration in the functionality and integrity of brain barriers is reported in various CNS diseases, as a cause or a consequence and in this regard, Li by itself is known to modulate BBB properties such as the expression and activity of various transporters, metabolizing enzymes, and the specialized tight junction proteins on BBB. In this review, we will focus on recent knowledge into the role of the brain barriers as key-element in the Li neuropharmacokinetics which might improve the understanding of PK-PD of Li and its interindividual variability in drug response.
Collapse
Affiliation(s)
- Huilong Luo
- Université de Paris, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France; Department of Chemical and Biological Engineering, University of Wisconsin-Madison, USA
| | - Lucie Chevillard
- Université de Paris, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France
| | - Frank Bellivier
- Université de Paris, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France; Department of Psychiatry, Lariboisière Hospital, AP-HP, 75010 Paris, France
| | - Bruno Mégarbane
- Université de Paris, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France; Department of Medical and Toxicological Critical Care, Lariboisière Hospital, AP-HP, 75010 Paris, France
| | - Bruno Etain
- Université de Paris, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France; Department of Psychiatry, Lariboisière Hospital, AP-HP, 75010 Paris, France
| | - Salvatore Cisternino
- Université de Paris, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France; Service de Pharmacie, AP-HP, Hôpital Necker, 149 Rue de Sèvres, 75015 Paris, France
| | - Xavier Declèves
- Université de Paris, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France; Biologie du Médicament, AP-HP, Hôpital Cochin, 27 rue du Faubourg, St. Jacques, 75679 Paris Cedex 14, France.
| |
Collapse
|
19
|
Balakirouchenane D, Khoudour N, Chouchana L, Chevillard L, Parat S, Declèves X. Pharmacokinetics of Baclofen in a Full-Term Newborn after Intrauterine Exposure: A Case Report. Neonatology 2021; 118:624-627. [PMID: 34569533 DOI: 10.1159/000518657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 07/16/2021] [Indexed: 11/19/2022]
Abstract
Intrauterine exposure to baclofen can lead to syndrome of withdrawal during the first days of the newborn. We report the case of a full-term baby exposed to baclofen during pregnancy. The mother was treated with baclofen 10 mg 4 times daily. Blood samples were collected from the mother before entering labor and from the baby at H0, H11, H31, and H102 after birth to measure baclofen concentrations and monitor its elimination. Baclofen maternal and neonate pharmacokinetics (PK) and placental transfer were assessed using a physiologically based PK model. Baclofen PK in the neonate after birth followed a monoexponential elimination with a half-life of 10 h, 3-fold longer than that in adults. The newborn was monitored for 11 days without experiencing any symptoms of withdrawal. Reducing baclofen dosing regimen of the mother to the lowest and therefore reducing fetal exposure to baclofen is essential. This case reports for the first time the baclofen pharmacokinetic profile in a newborn.
Collapse
Affiliation(s)
- David Balakirouchenane
- Biologie du Médicament et Toxicologie, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Universitaire Cochin, Paris, France
| | - Nihel Khoudour
- Biologie du Médicament et Toxicologie, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Universitaire Cochin, Paris, France
| | - Laurent Chouchana
- Service de Pharmacologie, Centre Régional de Pharmacovigilance, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Universitaire Cochin, Paris, France
| | - Lucie Chevillard
- Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
| | - Sophie Parat
- Service de Médecine et Réanimation néonatales, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Universitaire Cochin, Paris, France
| | - Xavier Declèves
- Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
| |
Collapse
|
20
|
Luo H, Saubamea B, Chasseigneaux S, Cochois V, Smirnova M, Glacial F, Perrière N, Chaves C, Cisternino S, Declèves X. Molecular and Functional Study of Transient Receptor Potential Vanilloid 1-4 at the Rat and Human Blood-Brain Barrier Reveals Interspecies Differences. Front Cell Dev Biol 2020; 8:578514. [PMID: 33262985 PMCID: PMC7686441 DOI: 10.3389/fcell.2020.578514] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 10/21/2020] [Indexed: 12/30/2022] Open
Abstract
Transient receptor potential vanilloid 1-4 (TRPV1-4) expression and functionality were investigated in brain microvessel endothelial cells (BMEC) forming the blood-brain barrier (BBB) from rat and human origins. In rat, Trpv1-4 were detected by qRT-PCR in the brain cortex, brain microvessels, and in primary cultures of brain microvessel endothelial cells [rat brain microvessel endothelial cells (rPBMEC)]. A similar Trpv1-4 expression profile in isolated brain microvessels and rPBMEC was found with the following order: Trpv4 > Trpv2 > Trpv3 > Trpv1. In human, TRPV1-4 were detected in the BBB cell line human cerebral microvessel endothelial cells D3 cells (hCMEC/D3) and in primary cultures of BMEC isolated from human adult and children brain resections [human brain microvascular endothelial cells (hPBMEC)], showing a similar TRPV1-4 expression profile in both hCMEC/D3 cells and hPBMECs as follow: TRPV2 > > TRPV4 > TRPV1 > TRPV3. Western blotting and immunofluorescence experiments confirmed that TRPV2 and TRPV4 are the most expressed TRPV isoforms in hCMEC/D3 cells with a clear staining at the plasma membrane. A fluorescent dye Fluo-4 AM ester was applied to record intracellular Ca2+ levels. TRPV4 functional activity was demonstrated in mediating Ca2+ influx under stimulation with the specific agonist GSK1016790A (ranging from 3 to 1000 nM, EC50 of 16.2 ± 4.5 nM), which was inhibited by the specific TRPV4 antagonist, RN1734 (30 μM). In contrast, TRPV1 was slightly activated in hCMEC/D3 cells as shown by the weak Ca2+ influx induced by capsaicin at a high concentration (3 μM), a highly potent and specific TRPV1 agonist. Heat-induced Ca2+ influx was not altered by co-treatment with a selective potent TRPV1 antagonist capsazepine (20 μM), in agreement with the low expression of TRPV1 as assessed by qRT-PCR. Our present study reveals an interspecies difference between Rat and Human. Functional contributions of TRPV1-4 subtype expression were not identical in rat and human tissues reflective of BBB integrity. TRPV2 was predominant in the human whereas TRPV4 had a larger role in the rat. This interspecies difference from a gene expression point of view should be taken into consideration when modulators of TRPV2 or TRPV4 are investigated in rat models of brain disorders.
Collapse
Affiliation(s)
- Huilong Luo
- Faculté de Pharmacie, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
- Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI, United States
| | - Bruno Saubamea
- Faculté de Pharmacie, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
| | - Stéphanie Chasseigneaux
- Faculté de Pharmacie, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
| | - Véronique Cochois
- Faculté de Pharmacie, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
| | - Maria Smirnova
- Faculté de Pharmacie, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
| | | | | | - Catarina Chaves
- Faculté de Pharmacie, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
| | - Salvatore Cisternino
- Faculté de Pharmacie, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
- Service Pharmacie, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker – Enfants Malades, Paris, France
| | - Xavier Declèves
- Faculté de Pharmacie, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France
- Biologie du médicament et toxicologie, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Universitaire Cochin, Paris, France
| |
Collapse
|
21
|
Chaves C, Campanelli F, Chapy H, Gomez-Zepeda D, Glacial F, Smirnova M, Taghi M, Pallud J, Perrière N, Declèves X, Menet MC, Cisternino S. An Interspecies Molecular and Functional Study of Organic Cation Transporters at the Blood-Brain Barrier: From Rodents to Humans. Pharmaceutics 2020; 12:pharmaceutics12040308. [PMID: 32231079 PMCID: PMC7238036 DOI: 10.3390/pharmaceutics12040308] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Revised: 03/16/2020] [Accepted: 03/25/2020] [Indexed: 01/11/2023] Open
Abstract
Organic cation transporters (OCTs) participate in the handling of compounds in kidneys and at the synaptic cleft. Their role at the blood-brain barrier (BBB) in brain drug delivery is still unclear. The presence of OCT1,2,3 (SLC22A1-3) in mouse, rat and human isolated brain microvessels was investigated by either qRT-PCR, quantitative proteomics and/or functional studies. BBB transport of the prototypical substrate [3H]-1-methyl-4-phenylpyridinium ([3H]-MPP+) was measured by in situ brain perfusion in six mouse strains and in Sprague Dawley rats, in primary human brain microvascular endothelial cells seeded on inserts, in the presence or absence of OCTs and a MATE1 (SLC49A1) inhibitor. The results show negligible OCT1 (SLC22A1) and OCT2 (SLC22A2) expression in either mice, rat or human brain microvessels, while OCT3 expression was identified in rat microvessels by qRT-PCR. The in vitro human cellular uptake of [3H]-MPP+ was not modified by OCTs/MATE-inhibitor. Brain transport of [3H]-MPP+ remains unchanged between 2- and 6-month old mice, and no alteration was observed in mice and rats with inhibitors. In conclusion, the evidenced lack of expression and/or functional OCTs and MATE at the BBB allows the maintenance of the brain homeostasis and function as it prevents an easy access of their neurotoxicant substrates to the brain parenchyma.
Collapse
Affiliation(s)
- Catarina Chaves
- Inserm, U1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (C.C.); (F.C.); (H.C.); (M.S.); (M.T.); (X.D.); (M.-C.M.)
- Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
| | - Federica Campanelli
- Inserm, U1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (C.C.); (F.C.); (H.C.); (M.S.); (M.T.); (X.D.); (M.-C.M.)
- Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
| | - Hélène Chapy
- Inserm, U1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (C.C.); (F.C.); (H.C.); (M.S.); (M.T.); (X.D.); (M.-C.M.)
- Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
| | - David Gomez-Zepeda
- Inserm, U1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (C.C.); (F.C.); (H.C.); (M.S.); (M.T.); (X.D.); (M.-C.M.)
- Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
| | - Fabienne Glacial
- BrainPlotting SAS, Institut du Cerveau et de la Moelle épinière, 75013 Paris, France; (F.G.); (N.P.)
| | - Maria Smirnova
- Inserm, U1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (C.C.); (F.C.); (H.C.); (M.S.); (M.T.); (X.D.); (M.-C.M.)
- Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
| | - Meryam Taghi
- Inserm, U1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (C.C.); (F.C.); (H.C.); (M.S.); (M.T.); (X.D.); (M.-C.M.)
- Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
| | - Johan Pallud
- Department of Neurosurgery, Sainte Anne Hospital, 75014 Paris, France;
- Inserm, U894, IMA-Brain, Centre de Psychiatrie et Neurosciences, 75013 Paris, France
| | - Nicolas Perrière
- BrainPlotting SAS, Institut du Cerveau et de la Moelle épinière, 75013 Paris, France; (F.G.); (N.P.)
| | - Xavier Declèves
- Inserm, U1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (C.C.); (F.C.); (H.C.); (M.S.); (M.T.); (X.D.); (M.-C.M.)
- Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
- Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpital Universitaire Cochin, Biologie du médicament et toxicologie, 75006 Paris, France
| | - Marie-Claude Menet
- Inserm, U1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (C.C.); (F.C.); (H.C.); (M.S.); (M.T.); (X.D.); (M.-C.M.)
- Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
- Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpital Universitaire Cochin, Hormonologie adulte, 75006 Paris, France
| | - Salvatore Cisternino
- Inserm, U1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France; (C.C.); (F.C.); (H.C.); (M.S.); (M.T.); (X.D.); (M.-C.M.)
- Faculté de pharmacie, Université de Paris, UMR-S 1144, 4, Avenue de l’Observatoire, 75006 Paris, France
- Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpital Universitaire Necker-Enfants Malades, Service de pharmacie, 75015 Paris, France
- Correspondence: ; Tel.: +33-1-444-951-91
| |
Collapse
|
22
|
Vignal N, Boulay AC, San C, Cohen-Salmon M, Rizzo-Padoin N, Sarda-Mantel L, Declèves X, Cisternino S, Hosten B. Astroglial Connexin 43 Deficiency Protects against LPS-Induced Neuroinflammation: A TSPO Brain µPET Study with [ 18F]FEPPA. Cells 2020; 9:cells9020389. [PMID: 32046185 PMCID: PMC7072124 DOI: 10.3390/cells9020389] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 01/27/2020] [Accepted: 02/03/2020] [Indexed: 02/08/2023] Open
Abstract
Astroglial connexin 43 (Cx43) has been recognized as a crucial immunoregulating factor in the brain. Its inactivation leads to a continuous immune recruitment, cytokine expression modification and a specific humoral autoimmune response against the astrocytic extracellular matrix but without brain lesions or cell lysis. To assess the impact of Cx43 deletion on the brain’s inflammatory response, TSPO expression was studied by positron emission tomography (PET) imaging with a specific radioligand, [18F]FEPPA, in basal conditions or upon Lipopolysaccharides (LPS)-induced inflammatory challenge. Astroglial Cx43-deleted mice underwent [18F]FEPPA PET/CT dynamic imaging with or without LPS injection (5 mg/kg) 24 h before imaging. Quantification and pharmacokinetic data modelling with a 2TCM-1K compartment model were performed. After collecting the mice brains, TSPO expression was quantified and localized by Western blot and FISH analysis. We found that astroglial Cx43 deficiency does not significantly alter TSPO expression in the basal state as observed with [18F]FEPPA PET imaging, FISH and Western blot analysis. However, deletion of astrocyte Cx43 abolishes the LPS-induced TSPO increase. Autoimmune encephalopathy observed in astroglial Cx43-deleted mice does not involve TSPO overexpression. Consistent with previous studies showing a unique inflammatory status in the absence of astrocyte Cx43, we show that a deficient expression of astrocytic Cx43 protects the animals from LPS-induced neuroinflammation as addressed by TSPO expression.
Collapse
Affiliation(s)
- Nicolas Vignal
- Unité Claude Kellershohn, Institut de Recherche Saint-Louis, Faculté de Santé, Université de Paris, 75010 Paris, France; (N.V.); (N.R.-P.); (L.S.-M.)
- Therapeutic Optimisation in Neuropsychopharmacology, INSERM UMR-S 1144, 75005 Paris, France; (X.D.); (S.C.)
- Hôpital Lariboisière: Service de médecine nucléaire, Assistance Publique–Hôpitaux de Paris, 75010 Paris, France
| | - Anne-Cécile Boulay
- Center for Interdisciplinary Research in Biology (CIRB), College de France, CNRS, INSERM, PSL Research University, 75005 Paris, France; (A.-C.B.); (M.C.-S.)
| | - Carine San
- Hôpital Saint-Louis: Service Pharmacie, Assistance Publique–Hôpitaux de Paris, Unité Claude Kellershohn, 75010 Paris, France;
| | - Martine Cohen-Salmon
- Center for Interdisciplinary Research in Biology (CIRB), College de France, CNRS, INSERM, PSL Research University, 75005 Paris, France; (A.-C.B.); (M.C.-S.)
| | - Nathalie Rizzo-Padoin
- Unité Claude Kellershohn, Institut de Recherche Saint-Louis, Faculté de Santé, Université de Paris, 75010 Paris, France; (N.V.); (N.R.-P.); (L.S.-M.)
- Therapeutic Optimisation in Neuropsychopharmacology, INSERM UMR-S 1144, 75005 Paris, France; (X.D.); (S.C.)
- Hôpital Saint-Louis: Service Pharmacie, Assistance Publique–Hôpitaux de Paris, Unité Claude Kellershohn, 75010 Paris, France;
| | - Laure Sarda-Mantel
- Unité Claude Kellershohn, Institut de Recherche Saint-Louis, Faculté de Santé, Université de Paris, 75010 Paris, France; (N.V.); (N.R.-P.); (L.S.-M.)
- Hôpital Lariboisière: Service de médecine nucléaire, Assistance Publique–Hôpitaux de Paris, 75010 Paris, France
| | - Xavier Declèves
- Therapeutic Optimisation in Neuropsychopharmacology, INSERM UMR-S 1144, 75005 Paris, France; (X.D.); (S.C.)
- Faculté de Santé, Université de Paris, 75005 Paris, France
- Hôpital Cochin: Service de biologie du médicament et de toxicologie, Assistance Publique–Hôpitaux de Paris, 75014 Paris, France
| | - Salvatore Cisternino
- Therapeutic Optimisation in Neuropsychopharmacology, INSERM UMR-S 1144, 75005 Paris, France; (X.D.); (S.C.)
- Faculté de Santé, Université de Paris, 75005 Paris, France
- Hôpital Necker–Enfants Malades: Service de pharmacie, Assistance Publique–Hôpitaux de Paris, 75015 Paris, France
| | - Benoît Hosten
- Unité Claude Kellershohn, Institut de Recherche Saint-Louis, Faculté de Santé, Université de Paris, 75010 Paris, France; (N.V.); (N.R.-P.); (L.S.-M.)
- Therapeutic Optimisation in Neuropsychopharmacology, INSERM UMR-S 1144, 75005 Paris, France; (X.D.); (S.C.)
- Hôpital Saint-Louis: Service Pharmacie, Assistance Publique–Hôpitaux de Paris, Unité Claude Kellershohn, 75010 Paris, France;
- Correspondence: ; Tel.: +33-142-385-105
| |
Collapse
|
23
|
Lafaye P, Lesuisse D, Declèves X. [New formats for improving brain drug delivery of antibodies: the blood-brain barrier case]. Med Sci (Paris) 2020; 35:1106-1112. [PMID: 31903924 DOI: 10.1051/medsci/2019223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Many neurodegenerative or tumor brain pathologies should be able to benefit from the impressive medicinal advances that represent therapeutic antibodies. Unfortunately, many failures have been observed with antibodies whose targets are in the brain parenchyma due to their very low brain distribution. The blood-brain barrier (BBB) that exhibits extremely selective and restrictive properties is responsible for the low brain penetration of high-molecular mass molecules including therapeutic antibodies. The objective of this article is to present the properties of the BBB and the latest advances in the engineering of new antibody formats to possibly improve their brain distribution.
Collapse
Affiliation(s)
- Pierre Lafaye
- Institut Pasteur, Plateforme d'ingénierie des anticorps, Paris, France
| | - Dominique Lesuisse
- Sanofi, Département des Maladies Rares et Neurologiques, Groupe Barrières Cérébrales, Paris, France
| | - Xavier Declèves
- Université Paris Descartes, Faculté de Pharmacie de Paris et Inserm UMRS-1144, Barrière hémato-encéphalique: Physiopathologie et Thérapie, Paris, France
| |
Collapse
|
24
|
Wulkersdorfer B, Bauer M, Karch R, Stefanits H, Philippe C, Weber M, Czech T, Menet MC, Declèves X, Hainfellner JA, Preusser M, Hacker M, Zeitlinger M, Müller M, Langer O. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. EJNMMI Res 2019; 9:110. [PMID: 31832814 PMCID: PMC6908538 DOI: 10.1186/s13550-019-0581-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Accepted: 12/04/2019] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) are two efflux transporters expressed at the blood-brain barrier which effectively restrict the brain distribution of the majority of currently known anticancer drugs. High-grade brain tumors often possess a disrupted blood-brain tumor barrier (BBTB) leading to enhanced accumulation of magnetic resonance imaging contrast agents, and possibly anticancer drugs, as compared to normal brain. In contrast to high-grade brain tumors, considerably less information is available with respect to BBTB integrity in lower grade brain tumors. MATERIALS AND METHODS We performed positron emission tomography imaging with the radiolabeled ABCB1 inhibitor [11C]tariquidar, a prototypical ABCB1/ABCG2 substrate, in seven patients with non-contrast -enhancing brain tumors (WHO grades I-III). In addition, ABCB1 and ABCG2 levels were determined in surgically resected tumor tissue of four patients using quantitative targeted absolute proteomics. RESULTS Brain distribution of [11C]tariquidar was found to be very low across the whole brain and not significantly different between tumor and tumor-free brain tissue. Only one patient showed a small area of enhanced [11C]tariquidar uptake within the brain tumor. ABCG2/ABCB1 ratios in surgically resected tumor tissue (1.4 ± 0.2) were comparable to previously reported ABCG2/ABCB1 ratios in isolated human micro-vessels (1.3), which suggested that no overexpression of ABCB1 or ABCG2 occurred in the investigated tumors. CONCLUSIONS Our data suggest that the investigated brain tumors had an intact BBTB, which is impermeable to anticancer drugs, which are dual ABCB1/ABCG2 substrates. Therefore, effective drugs for antitumor treatment should have high passive permeability and lack ABCB1/ABCG2 substrate affinity. TRIAL REGISTRATION European Union Drug Regulating Authorities Clinical Trials Database (EUDRACT), 2011-004189-13. Registered on 23 February 2012, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004189-13.
Collapse
Affiliation(s)
| | - Martin Bauer
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Rudolf Karch
- Centre for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria
| | - Harald Stefanits
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| | - Cécile Philippe
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Maria Weber
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Thomas Czech
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| | - Marie-Claude Menet
- Inserm, U1144, Paris, France.,Université Paris Descartes, UMR-S 1144, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Xavier Declèves
- Inserm, U1144, Paris, France.,Université Paris Descartes, UMR-S 1144, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | | | - Matthias Preusser
- Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
| | - Marcus Hacker
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Markus Zeitlinger
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Markus Müller
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Oliver Langer
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. .,Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. .,Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
| |
Collapse
|
25
|
Lloret-Linares C, Daali Y, Abbara C, Carette C, Bouillot JL, Vicaut E, Czernichow S, Declèves X. CYP450 activities before and after Roux-en-Y gastric bypass: correlation with their intestinal and liver content. Surg Obes Relat Dis 2019; 15:1299-1310. [PMID: 31262651 DOI: 10.1016/j.soard.2019.05.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 05/06/2019] [Accepted: 05/09/2019] [Indexed: 02/08/2023]
|
26
|
Delaleu J, Destere A, Hachon L, Declèves X, Lloret-Linares C. Glucocorticoids dosing in obese subjects: A systematic review. Therapie 2019; 74:451-458. [PMID: 30928086 DOI: 10.1016/j.therap.2018.11.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 10/08/2018] [Accepted: 11/19/2018] [Indexed: 12/18/2022]
Abstract
Glucocorticoids (GCs) are amongst the most widely used and effective treatments to control inflammatory and autoimmune diseases. In obese subjects, drug dosing adjusted by body weight is problematic, all the more so as patients are at higher risk of GC metabolic side effects. We propose here to describe the determinants of drug pharmacokinetics (PK) in obese subjects and GC pharmacology, and to identify the existing PK studies that may help discussing the best size descriptor for GC dosing in obese subjects. A clinician and a pharmacist screened PubMed using the MeSH Terms: "glucocorticoids" OR "steroidal agents" AND "pharmacokinetics" AND "obesity" OR "overweight". The search was limited to the publications written in English language and to those performed in humans. A systematic search using the MeSH terms was performed until August 31st, 2017. Only three such PK studies have been published so far that compare dexamethasone, prednisolone and methylprednisolone in obese and normal weight subjects. The studies concur that GC partially distribute in the excess of body weight and that adjustment by total body weight (TBW) or by body weight (BW) excess would increase the initial plasma GC concentration after a loading dose and would thus be inappropriate. Contradictory results are observed regarding GC exposure or clearance according to the GC studied. Behind this overwhelming lack of conclusive evidence for adjusting GC by body weight, further PK studies are clearly needed for guiding their dosing. Furthermore, studies demonstrated an increased sensibility to GC, even when GC exposure was reduced, suggesting that adjustment by body weight may not only be unnecessary but also dangerous.
Collapse
Affiliation(s)
- Jérémie Delaleu
- Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Department of Internal Medicine, 75010 Paris, France
| | - Alexandre Destere
- CHU de Limoges, Department of Pharmacology and Toxicology, 87000 Limoges, France
| | - Lorry Hachon
- Assistance Publique-Hôpitaux de Paris (AP-HP), Pharmacy Department, Hôpital Cochin, 75014 Paris, France
| | - Xavier Declèves
- INSERM, UMR-S 1144 Université Paris Descartes-Paris Diderot, variabilité de réponse aux psychotropes, 75006 Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Pharmacokinetics and Pharmacochemistry Unit, 75014 Paris, France
| | - Célia Lloret-Linares
- Groupe Ramsay-Générale de Santé, Hôpital Privé Pays de Savoie, Maladies Nutritionnelles et Métaboliques, 74100 Annemasse, France.
| |
Collapse
|
27
|
Benturquia N, Chevillard L, Poiré C, Roussel O, Cohier C, Declèves X, Laplanche JL, Etheve-Quelquejeu M, Chen H, Mégarbane B. Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. Psychopharmacology (Berl) 2019; 236:891-901. [PMID: 29971461 DOI: 10.1007/s00213-018-4962-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 06/27/2018] [Indexed: 01/07/2023]
Abstract
RATIONALE The use of synthetic cathinones as recreational drugs frequently sold in combination has been increasing exponentially. However, the consequences of combining cathinones on the resulting stimulant effects and the pharmacokinetics have been poorly investigated. OBJECTIVE AND METHODS To study 3,4-methylenedioxypyrovalerone (MDPV; 3 mg/kg) and mephedrone (4-MMC; 30 mg/kg)-induced effects on rat locomotor activity and pharmacokinetics, administered alone or in combination by the intragastric route. The pharmacokinetic parameters were determined using non-compartmental analysis and the relationships between the locomotor activity and drug concentrations using sigmoidal Emax modeling. RESULTS Locomotor activity significantly increased during the first hour post-administration with the MDPV/4-MMC combination in comparison to MDPV (p < 0.001) and 4-MMC (p < 0.01) alone. The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone. The sigmoidal Emax model fitted the observed data well; MDPV being markedly more potent than 4-MMC (EC50, 0.043 versus 0.7 μmol/L). The enhancing factor representing the MDPV contribution to the alteration in the relationships between locomotor activity and 4-MMC concentrations was 0.3. CONCLUSION An MDPV/4-MMC combination results in enhanced stimulant effects in the rat, despite significant reduction in MDPV bioavailability. Enhanced effects could be explained by increased MDPV distribution and/or possible complementation at the brain dopaminergic targets. However, the exact consequences of the MDPV/4-MMC combination in humans remain to be clarified.
Collapse
Affiliation(s)
- Nadia Benturquia
- Inserm, UMR-S 1144, Paris-Descartes and Paris-Diderot Universities, Paris, France
| | - Lucie Chevillard
- Inserm, UMR-S 1144, Paris-Descartes and Paris-Diderot Universities, Paris, France
| | - Christophe Poiré
- Inserm, UMR-S 1144, Paris-Descartes and Paris-Diderot Universities, Paris, France.,CNRS, UMR8601, Laboratory of Chemistry and Pharmacological and Toxicological Biochemistry, CBNIT, Paris-Descartes University, Paris, France
| | - Olivier Roussel
- Inserm, UMR-S 1144, Paris-Descartes and Paris-Diderot Universities, Paris, France.,Toxicology Department, Institut de Recherche Criminelle de la Gendarmerie Nationale, Rosny sous-Bois, France
| | - Camille Cohier
- Inserm, UMR-S 1144, Paris-Descartes and Paris-Diderot Universities, Paris, France.,Toxicology Department, Institut de Recherche Criminelle de la Gendarmerie Nationale, Rosny sous-Bois, France
| | - Xavier Declèves
- Inserm, UMR-S 1144, Paris-Descartes and Paris-Diderot Universities, Paris, France
| | - Jean-Louis Laplanche
- Inserm, UMR-S 1144, Paris-Descartes and Paris-Diderot Universities, Paris, France
| | - Mélanie Etheve-Quelquejeu
- CNRS, UMR8601, Laboratory of Chemistry and Pharmacological and Toxicological Biochemistry, CBNIT, Paris-Descartes University, Paris, France
| | - Huixiong Chen
- CNRS, UMR8601, Laboratory of Chemistry and Pharmacological and Toxicological Biochemistry, CBNIT, Paris-Descartes University, Paris, France
| | - Bruno Mégarbane
- Inserm, UMR-S 1144, Paris-Descartes and Paris-Diderot Universities, Paris, France. .,Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris, France.
| |
Collapse
|
28
|
Luo H, Rossi E, Saubamea B, Chasseigneaux S, Cochois V, Choublier N, Smirnova M, Glacial F, Perrière N, Bourdoulous S, Smadja DM, Menet MC, Couraud PO, Cisternino S, Declèves X. Cannabidiol Increases Proliferation, Migration, Tubulogenesis, and Integrity of Human Brain Endothelial Cells through TRPV2 Activation. Mol Pharm 2019; 16:1312-1326. [PMID: 30721081 DOI: 10.1021/acs.molpharmaceut.8b01252] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The effect of cannabidiol (CBD), a high-affinity agonist of the transient receptor potential vanilloid-2 (TRPV2) channel, has been poorly investigated in human brain microvessel endothelial cells (BMEC) forming the blood-brain barrier (BBB). TRPV2 expression and its role on Ca2+ cellular dynamics, trans-endothelial electrical resistance (TEER), cell viability and growth, migration, and tubulogenesis were evaluated in human primary cultures of BMEC (hPBMEC) or in the human cerebral microvessel endothelial hCMEC/D3 cell line. Abundant TRPV2 expression was measured in hCMEC/D3 and hPBMEC by qRT-PCR, Western blotting, nontargeted proteomics, and cellular immunofluorescence studies. Intracellular Ca2+ levels were increased by heat and CBD and blocked by the nonspecific TRP antagonist ruthenium red (RR) and the selective TRPV2 inhibitor tranilast (TNL) or by silencing cells with TRPV2 siRNA. CBD dose-dependently induced the hCMEC/D3 cell number (EC50 0.3 ± 0.1 μM), and this effect was fully abolished by TNL or TRPV2 siRNA. A wound healing assay showed that CBD induced cell migration, which was also inhibited by TNL or TRPV2 siRNA. Tubulogenesis of hCMEC/D3 cells in 3D matrigel cultures was significantly increased by 41 and 73% after a 7 or 24 h CBD treatment, respectively, and abolished by TNL. CBD also increased the TEER of hPBMEC monolayers cultured in transwell, and this was blocked by TNL. Our results show that CBD, at extracellular concentrations close to those observed in plasma of patients treated by CBD, induces proliferation, migration, tubulogenesis, and TEER increase in human brain endothelial cells, suggesting CBD might be a potent target for modulating the human BBB.
Collapse
Affiliation(s)
- Huilong Luo
- Inserm , U1144 , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1144 , Paris F-75006 , France.,Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France
| | - Elisa Rossi
- Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1140 , Paris F-75006 , France
| | - Bruno Saubamea
- Inserm , U1144 , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1144 , Paris F-75006 , France.,Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France
| | - Stéphanie Chasseigneaux
- Inserm , U1144 , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1144 , Paris F-75006 , France.,Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France
| | - Véronique Cochois
- Inserm , U1144 , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1144 , Paris F-75006 , France.,Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France
| | - Nina Choublier
- Inserm , U1144 , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1144 , Paris F-75006 , France.,Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France
| | - Maria Smirnova
- Inserm , U1144 , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1144 , Paris F-75006 , France.,Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France
| | | | | | - Sandrine Bourdoulous
- Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France.,Department of Infection, Institut Cochin , Inserm, U1016 , Paris F-75014 , France.,CNRS, UMR 8104 , Paris F-75014 , France
| | - David M Smadja
- Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1140 , Paris F-75006 , France.,Hematology Department , AP-HP, Hôpital Européen Georges Pompidou , INSERM UMR-S 1140 , Paris F-75015 , France
| | - Marie-Claude Menet
- Inserm , U1144 , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1144 , Paris F-75006 , France.,Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France
| | - Pierre-Olivier Couraud
- Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France.,Department of Infection, Institut Cochin , Inserm, U1016 , Paris F-75014 , France.,CNRS, UMR 8104 , Paris F-75014 , France
| | - Salvatore Cisternino
- Inserm , U1144 , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1144 , Paris F-75006 , France.,Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France
| | - Xavier Declèves
- Inserm , U1144 , Paris F-75006 , France.,Université Paris Descartes , UMR-S 1144 , Paris F-75006 , France.,Université Paris Descartes , Sorbonne Paris Cité , Paris F-75006 , France
| |
Collapse
|
29
|
Goutal S, Langer O, Auvity S, Andrieux K, Coulon C, Caillé F, Gervais P, Cisternino S, Declèves X, Tournier N. Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates. Drug Deliv Transl Res 2018; 8:536-542. [PMID: 29294257 DOI: 10.1007/s13346-017-0472-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Elacridar (GF120918) is a highly potent inhibitor of both P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), the main efflux transporters expressed at the blood-brain barrier (BBB). Elacridar shows very low aqueous solubility, which complicates its formulation for i.v. administration. An intravenous infusion protocol would be preferred to achieve high and controlled plasma concentrations of elacridar in large animals, including nonhuman primates. Formulation of elacridar for i.v. infusion was achieved using a co-solvent strategy, resulting in an aqueous dispersion with a final concentration of 5 g L-1 elacridar with tetrahydrofuran (5% w/v) in aqueous D-glucose solution (2.5%, w/v). Particle size (mean = 2.8 ± 0.9 μm) remained stable for 150 min. The preparation was i.v. administered as a continuous infusion (12 mg kg-1 h-1 for 90 min) to three baboons. Arterial and venous plasma pharmacokinetics (PK) of elacridar were monitored using a newly developed and validated HPLC-UV method. Elacridar concentration increased rapidly to reach a plateau at 9.5 μg mL-1 within 20 min after the start of infusion. Elacridar PK in venous plasma did not differ from arterial plasma facing the BBB, indicating the absence of an arteriovenous concentration gradient. Intravenous infusion of elacridar allows for controlled exposure of the BBB and offers a useful tool to assess the impact of ABCB1/ABCG2 on drug disposition to the brain in nonhuman primates, a relevant animal model for the study of transporter function at the BBB.
Collapse
Affiliation(s)
- Sébastien Goutal
- IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France.,CEA/DRF/Institut de Biologie François Jacob/MIRCen, Fontenay-aux-Roses, France
| | - Oliver Langer
- Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.,Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.,Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
| | - Sylvain Auvity
- IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France.,Variabilité de Réponse aux Psychotropes, INSERM, U1144, 75006, Paris, France.,Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 75006, Paris, France
| | - Karine Andrieux
- Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 75006, Paris, France.,UTCBS, CNRS UMR 8258, Inserm U1022, 75006, Paris, France
| | - Christine Coulon
- IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France
| | - Fabien Caillé
- IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France
| | - Philippe Gervais
- IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France
| | - Salvatore Cisternino
- Variabilité de Réponse aux Psychotropes, INSERM, U1144, 75006, Paris, France.,Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 75006, Paris, France
| | - Xavier Declèves
- Variabilité de Réponse aux Psychotropes, INSERM, U1144, 75006, Paris, France.,Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 75006, Paris, France
| | - Nicolas Tournier
- IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France. .,CEA/DRF/JOLIOT/Service Hospitalier Frédéric Joliot, 91406, Orsay, France.
| |
Collapse
|
30
|
Krohn M, Wanek T, Menet MC, Noack A, Declèves X, Langer O, Löscher W, Pahnke J. Humanization of the Blood-Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus - Lessons from Three Unsuccessful Approaches. Eur J Microbiol Immunol (Bp) 2018; 8:78-86. [PMID: 30345087 PMCID: PMC6186017 DOI: 10.1556/1886.2018.00008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Accepted: 05/16/2018] [Indexed: 01/16/2023] Open
Abstract
ATP-binding cassette (ABC) transporters are of major importance for the restricted access of toxins and drugs to the human body. At the body's barrier tissues like the blood-brain barrier, these transporters are highly represented. Especially, ABCB1 (P-glycoprotein) has been a priority target of pharmaceutical research, for instance, to aid chemotherapy of cancers, therapy resistant epilepsy, and lately even neurodegenerative diseases. To improve translational research, the humanization of mouse genes has become a popular tool although, like recently seen for Abcb1, not all approaches were successful. Here, we report the characterization of another unsuccessful commercially available ABCB1 humanized mouse strain. In vivo assessment of transporter activity using positron emission tomography imaging revealed a severe reduction of ABCB1 function in the brain of these mice. Analyses of brain mRNA and protein expression showed that the murine Abcb1a gene is still expressed in homozygous humanized animals while expression of the human gene is minimal. Promoter region analyses underpinned that the introduced human gene might dysregulate normal expression and provided insights into the regulation of both transcription and translation of Abcb1a. We conclude that insertion of the human coding DNA sequence (CDS) into exon 3 instead of exon 2 most probably represents a more promising strategy for Abcb1a humanization.
Collapse
Affiliation(s)
- Markus Krohn
- Translational Neurodegeneration Research and Neuropathology Lab, Department of Neuro-Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Thomas Wanek
- Center for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria
| | - Marie-Claude Menet
- Inserm UMR-S 1144, Faculté de Pharmacie, Université Paris Descartes, Paris, France
| | - Andreas Noack
- Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, Hannover, Germany
| | - Xavier Declèves
- Inserm UMR-S 1144, Faculté de Pharmacie, Université Paris Descartes, Paris, France
| | - Oliver Langer
- Center for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
| | - Wolfgang Löscher
- Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, Hannover, Germany
- Center for Systems Neuroscience, Hannover, Germany
| | - Jens Pahnke
- Translational Neurodegeneration Research and Neuropathology Lab, Department of Neuro-Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway
- LIED, University of Lübeck, Lübeck, Germany
- Department of Bioorganic Chemistry, Leibniz-Institute of Plant Biochemistry, Halle, Germany
- Department of Pharmacology, University of Latvia, Riga, Latvia
| |
Collapse
|
31
|
Luo H, Gauthier M, Tan X, Landry C, Poupon J, Dehouck MP, Gosselet F, Perrière N, Bellivier F, Cisternino S, Declèves X. Sodium Transporters Are Involved in Lithium Influx in Brain Endothelial Cells. Mol Pharm 2018; 15:2528-2538. [DOI: 10.1021/acs.molpharmaceut.8b00018] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Huilong Luo
- Inserm U1144, Paris F-75006, France
- Université Paris Descartes UMR-S 1144, Paris F-75006, France
| | - Matthieu Gauthier
- Inserm U1144, Paris F-75006, France
- Université Paris Descartes UMR-S 1144, Paris F-75006, France
| | - Xi Tan
- Inserm U1144, Paris F-75006, France
- Université Paris Descartes UMR-S 1144, Paris F-75006, France
| | - Christophe Landry
- Laboratoire de la Barrière Hémato-Encéphalique (LBHE), Université Artois EA 2465, F-62300 Lens, France
| | - Joël Poupon
- Laboratoire de Toxicologie, Hôpital Lariboisière, Paris 75010, France
| | - Marie-Pierre Dehouck
- Laboratoire de la Barrière Hémato-Encéphalique (LBHE), Université Artois EA 2465, F-62300 Lens, France
| | - Fabien Gosselet
- Laboratoire de la Barrière Hémato-Encéphalique (LBHE), Université Artois EA 2465, F-62300 Lens, France
| | | | - Frank Bellivier
- Inserm U1144, Paris F-75006, France
- Université Paris Diderot UMR-S 1144, Paris F-75006, France
| | - Salvatore Cisternino
- Inserm U1144, Paris F-75006, France
- Université Paris Descartes UMR-S 1144, Paris F-75006, France
| | - Xavier Declèves
- Inserm U1144, Paris F-75006, France
- Université Paris Descartes UMR-S 1144, Paris F-75006, France
| |
Collapse
|
32
|
Vignal N, Cisternino S, Rizzo-Padoin N, San C, Hontonnou F, Gelé T, Declèves X, Sarda-Mantel L, Hosten B. [ 18F]FEPPA a TSPO Radioligand: Optimized Radiosynthesis and Evaluation as a PET Radiotracer for Brain Inflammation in a Peripheral LPS-Injected Mouse Model. Molecules 2018; 23:molecules23061375. [PMID: 29875332 PMCID: PMC6099542 DOI: 10.3390/molecules23061375] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 05/25/2018] [Accepted: 06/04/2018] [Indexed: 01/17/2023] Open
Abstract
[18F]FEPPA is a specific ligand for the translocator protein of 18 kDa (TSPO) used as a positron emission tomography (PET) biomarker for glial activation and neuroinflammation. [18F]FEPPA radiosynthesis was optimized to assess in a mouse model the cerebral inflammation induced by an intraperitoneal injection of Salmonella enterica serovar Typhimurium lipopolysaccharides (LPS; 5 mg/kg) 24 h before PET imaging. [18F]FEPPA was synthesized by nucleophilic substitution (90 °C, 10 min) with tosylated precursor, followed by improved semi-preparative HPLC purification (retention time 14 min). [18F]FEPPA radiosynthesis were carried out in 55 min (from EOB). The non-decay corrected radiochemical yield were 34 ± 2% (n = 17), and the radiochemical purity greater than 99%, with a molar activity of 198 ± 125 GBq/µmol at the end of synthesis. Western blot analysis demonstrated a 2.2-fold increase in TSPO brain expression in the LPS treated mice compared to controls. This was consistent with the significant increase of [18F]FEPPA brain total volume of distribution (VT) estimated with pharmacokinetic modelling. In conclusion, [18F]FEPPA radiosynthesis was implemented with high yields. The new purification/formulation with only class 3 solvents is more suitable for in vivo studies.
Collapse
Affiliation(s)
- Nicolas Vignal
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Unité Claude Kellershohn, 75010 Paris, France.
- Inserm UMR-S 1144, Faculté de Pharmacie de Paris, Université Paris Descartes, 75006 Paris, France.
| | - Salvatore Cisternino
- Inserm UMR-S 1144, Faculté de Pharmacie de Paris, Université Paris Descartes, 75006 Paris, France.
- Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France.
| | - Nathalie Rizzo-Padoin
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Unité Claude Kellershohn, 75010 Paris, France.
- Inserm UMR-S 1144, Faculté de Pharmacie de Paris, Université Paris Descartes, 75006 Paris, France.
| | - Carine San
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Unité Claude Kellershohn, 75010 Paris, France.
| | - Fortune Hontonnou
- Institut Universitaire d'Hématologie, Université Paris Diderot, 75013 Paris, France.
| | - Thibaut Gelé
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Unité Claude Kellershohn, 75010 Paris, France.
| | - Xavier Declèves
- Inserm UMR-S 1144, Faculté de Pharmacie de Paris, Université Paris Descartes, 75006 Paris, France.
- Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, 75014 Paris, France.
| | - Laure Sarda-Mantel
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Unité Claude Kellershohn, 75010 Paris, France.
- Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Médecine Nucléaire, 75010 Paris, France.
- Inserm UMR-S 942, Université Paris Diderot, 75013 Paris, France.
| | - Benoît Hosten
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Unité Claude Kellershohn, 75010 Paris, France.
- Inserm UMR-S 1144, Faculté de Pharmacie de Paris, Université Paris Descartes, 75006 Paris, France.
| |
Collapse
|
33
|
Taccola C, Cartot-Cotton S, Valente D, Barneoud P, Aubert C, Boutet V, Gallen F, Lochus M, Nicolic S, Dodacki A, Smirnova M, Cisternino S, Declèves X, Bourasset F. High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier. Eur J Pharm Sci 2018; 117:68-79. [DOI: 10.1016/j.ejps.2018.02.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Revised: 12/21/2017] [Accepted: 02/05/2018] [Indexed: 11/28/2022]
|
34
|
Gourdon B, Declèves X, Péan JM, Chemin C. Double or Simple Emulsion Process to Encapsulate Hydrophilic Oxytocin Peptide in PLA-PEG Nanoparticles. Pharm Res 2018; 35:82. [PMID: 29508092 DOI: 10.1007/s11095-018-2358-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Accepted: 01/31/2018] [Indexed: 01/27/2023]
Abstract
PURPOSE Oral drug delivery using NPs is a current strategy for poorly absorbed molecules. It offers significant improvement in terms of bioavailability. However, the encapsulation of proteins and peptides in polymeric NPs is a challenge. Firstly, the present study focused on the double emulsion process in order to encapsulate the OXY peptide. Then the technique was challenged by a one-step simplified process, the simple emulsion. METHODS In order to study the influence of formulation and process parameters, factorial experimental designs were carried on. The responses observed were the NP size (<200 nm in order to penetrate the intestinal mucus layer), the suspension stability (ZP < |30| mV) and the OXY loading. RESULTS It was thus found that the amount and the nature of surfactant, the ratio between the phases, the amount of PLA-PEG polymer and OXY, the presence of a viscosifying agent, and the duration of the sonication could significantly influence the responses. Finally, OXY-loaded NPs from both processes were obtained with NP size of 195 and 226 nm and OXY loading of 4 and 3.3% for double and simple emulsions, respectively. CONCLUSION The two processes appeared to be suitable for OXY encapsulation and comparable in term of NP size, peptide drug load and release obtained.
Collapse
Affiliation(s)
- Betty Gourdon
- Technologie Servier, 27 rue Eugène Vignat, Orléans, France.,Inserm, U1144, F-75006, Paris, France.,Faculté de Pharmacie de Paris, UMR-S 1144, Université Paris Descartes, F-75006, Paris, France
| | - Xavier Declèves
- Inserm, U1144, F-75006, Paris, France. .,Faculté de Pharmacie de Paris, UMR-S 1144, Université Paris Descartes, F-75006, Paris, France. .,Inserm UMR-S1144, Universités Paris Descartes et Paris Diderot, 4 avenue de l'observatoire, 75006, Paris, France.
| | | | | |
Collapse
|
35
|
Martinez L, Vorspan F, Declèves X, Azuar J, Fortias M, Questel F, Dereux A, Grichy L, Barreteau H, Bellivier F, Lépine JP, Bloch V. An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with vs. without chronic pretreatment with high-dosage baclofen. Fundam Clin Pharmacol 2018; 32:200-205. [DOI: 10.1111/fcp.12339] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Revised: 11/13/2017] [Accepted: 12/05/2017] [Indexed: 12/18/2022]
Affiliation(s)
- Laura Martinez
- Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Service de Pharmacie; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Florence Vorspan
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| | - Xavier Declèves
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| | - Julien Azuar
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Maeva Fortias
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Franck Questel
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Alexandra Dereux
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Leslie Grichy
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Hélène Barreteau
- Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Service de Pharmacie; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
| | - Frank Bellivier
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| | - Jean-Pierre Lépine
- Département de Psychiatrie et de Médecine Addictologique; Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| | - Vanessa Bloch
- Groupe Hospitalier Saint-Louis- Lariboisière - Fernand Widal; Service de Pharmacie; Assistance Publique - Hôpitaux de Paris; 200 rue du Faubourg Saint Denis Paris 75010 France
- INSERM UMRS 1144 Variabilité de Réponse aux Psychotropes; PRES Sorbonne Paris Cité; Université Paris Descartes, Université Paris Diderot; 6 avenue de l'Observatoire Paris 75006 France
| |
Collapse
|
36
|
Hachon L, Declèves X, Faucher P, Carette C, Lloret-Linares C. RYGB and Drug Disposition: How to Do Better? Analysis of Pharmacokinetic Studies and Recommendations for Clinical Practice. Obes Surg 2017; 27:1076-1090. [PMID: 28124236 DOI: 10.1007/s11695-016-2535-z] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
An important issue in the follow-up of patients with bariatric surgery remains to determine whether their therapeutic management should be different after surgery. In this article, we first reviewed all pharmacokinetic studies involving at least four subjects who underwent the Roux-en-Y gastric bypass (RYGB) bariatric surgery. Twenty-five publications were selected and, overall, 25 drugs were studied. Drug solubility and permeability parameters for each drug were defined using different parameters or classifications. Increased rates of oral drug absorption were predominantly observed. Conversely, drug exposure differed from one drug to another. Considering the galenic formulation and the Biopharmaceutics Classification System (BCS) class may help the prediction of oral drug exposure outcome after RYGB. We propose a strategy aiming to guide prescription and drug monitoring in patients with RYGB. But further research is clearly needed due to the unique characteristics of the bariatric population. Priority should be given to drugs that do not have clinical or biological surrogates for dose adaptation.
Collapse
Affiliation(s)
- Lorry Hachon
- Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Therapeutic Research Unit, Department of Internal Medicine, Paris, F-75010, France.,Inserm, UMR-S 1144 Université Paris Descartes-Paris Diderot, Variabilité de réponse aux psychotropes, Paris, France
| | - Xavier Declèves
- Inserm, UMR-S 1144 Université Paris Descartes-Paris Diderot, Variabilité de réponse aux psychotropes, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Pharmacokinetics and Pharmacochemistry Unit, Paris, F-75014, France
| | - Pauline Faucher
- Nutrition Department, Assistance Publique-Hôpitaux de Paris, Hôpital La Pitié Salpêtrière, Paris, France
| | - Claire Carette
- Nutrition Department, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Célia Lloret-Linares
- Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Therapeutic Research Unit, Department of Internal Medicine, Paris, F-75010, France. .,Inserm, UMR-S 1144 Université Paris Descartes-Paris Diderot, Variabilité de réponse aux psychotropes, Paris, France.
| |
Collapse
|
37
|
Chevillard L, Sabo N, Tod M, Labat L, Chasport C, Chevaleyre C, Thibaut F, Barré J, Azuar J, Questel F, Vorspan F, Bloch V, Bellivier F, Granger B, Barrault C, Declèves X. Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients. Fundam Clin Pharmacol 2017; 32:239-248. [DOI: 10.1111/fcp.12330] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Revised: 09/16/2017] [Accepted: 10/24/2017] [Indexed: 12/19/2022]
Affiliation(s)
- Lucie Chevillard
- Inserm; UMR-S 1144; Université Paris Descartes - Paris Diderot; Variabilité de Réponse Aux Psychotropes; Paris F-75006 France
| | - Naomi Sabo
- Biologie du Médicament et Toxicologie; Hôpital Cochin; Assistance Publique-Hôpitaux de Paris; Paris F-75014 France
| | - Michel Tod
- EMR 3738; Ciblage Thérapeutique en Oncologie; Faculté de Médecine et de Maïeutique Lyon-Sud; Université Lyon 1; Oullins F-69600 France
- Pharmacie; Hôpital de la Croix Rousse; Hospices Civils de Lyon; Lyon F-69000 France
| | - Laurence Labat
- Inserm; UMR-S 1144; Université Paris Descartes - Paris Diderot; Variabilité de Réponse Aux Psychotropes; Paris F-75006 France
- Biologie du Médicament et Toxicologie; Hôpital Cochin; Assistance Publique-Hôpitaux de Paris; Paris F-75014 France
| | - Céline Chasport
- Biologie du Médicament et Toxicologie; Hôpital Cochin; Assistance Publique-Hôpitaux de Paris; Paris F-75014 France
| | - Céline Chevaleyre
- Biologie du Médicament et Toxicologie; Hôpital Cochin; Assistance Publique-Hôpitaux de Paris; Paris F-75014 France
| | - Florence Thibaut
- Service de Psychiatrie et Médecine Addictologique; Hôpital Lariboisière; Assistance Publique-Hôpitaux de Paris; Paris F-75010 France
| | - Jérôme Barré
- Centre Hospitalier Intercommunal de Créteil; Service Centre de Ressources Biologiques; Créteil F-94000 France
| | - Julien Azuar
- Service de Psychiatrie et Médecine Addictologique; Hôpital Lariboisière; Assistance Publique-Hôpitaux de Paris; Paris F-75010 France
| | - Franck Questel
- Inserm; UMR-S 1144; Université Paris Descartes - Paris Diderot; Variabilité de Réponse Aux Psychotropes; Paris F-75006 France
- Service de Psychiatrie et Médecine Addictologique; Hôpital Lariboisière; Assistance Publique-Hôpitaux de Paris; Paris F-75010 France
| | - Florence Vorspan
- Inserm; UMR-S 1144; Université Paris Descartes - Paris Diderot; Variabilité de Réponse Aux Psychotropes; Paris F-75006 France
- Service de Psychiatrie et Médecine Addictologique; Hôpital Lariboisière; Assistance Publique-Hôpitaux de Paris; Paris F-75010 France
| | - Vanessa Bloch
- Inserm; UMR-S 1144; Université Paris Descartes - Paris Diderot; Variabilité de Réponse Aux Psychotropes; Paris F-75006 France
| | - Frank Bellivier
- Inserm; UMR-S 1144; Université Paris Descartes - Paris Diderot; Variabilité de Réponse Aux Psychotropes; Paris F-75006 France
- Service de Psychiatrie et Médecine Addictologique; Hôpital Lariboisière; Assistance Publique-Hôpitaux de Paris; Paris F-75010 France
| | - Bernard Granger
- Service de Psychiatrie; Hôpital Tarnier; Assistance Publique-Hôpitaux de Paris; Paris F-75014 France
| | - Camille Barrault
- Centre Hospitalier Intercommunal de Créteil; Service Centre de Ressources Biologiques; Créteil F-94000 France
- Centre Hospitalier Intercommunal de Créteil; Service d'addictologie et hépato-gastro-entérologie; Créteil F-94000 France
| | - Xavier Declèves
- Inserm; UMR-S 1144; Université Paris Descartes - Paris Diderot; Variabilité de Réponse Aux Psychotropes; Paris F-75006 France
- Biologie du Médicament et Toxicologie; Hôpital Cochin; Assistance Publique-Hôpitaux de Paris; Paris F-75014 France
| |
Collapse
|
38
|
Marie S, Cisternino S, Buvat I, Declèves X, Tournier N. Imaging Probes and Modalities for the Study of Solute Carrier O (SLCO)-Transport Function In Vivo. J Pharm Sci 2017; 106:2335-2344. [DOI: 10.1016/j.xphs.2017.04.031] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Revised: 04/04/2017] [Accepted: 04/17/2017] [Indexed: 01/26/2023]
|
39
|
Hachon L, Reis R, Labat L, Poitou C, Jacob A, Declèves X, Lloret-Linares C. Morphine and metabolites plasma levels after administration of sustained release morphine in Roux-en-Y gastric bypass subjects versus matched control subjects. Surg Obes Relat Dis 2017; 13:1869-1874. [PMID: 28864105 DOI: 10.1016/j.soard.2017.07.030] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Revised: 07/18/2017] [Accepted: 07/25/2017] [Indexed: 12/31/2022]
Abstract
BACKGROUND Better knowledge of opioid pharmacology after Roux-en-Y gastric bypass (RYGB) is required for optimizing their use in this growing population. OBJECTIVE The aim of this case-controlled pharmacokinetic (PK) study was to compare morphine and its glucuronidated metabolites (morphine-3-glucuronide and morphine-6-glucuronide) plasma PKs between patients with RYGB and their controls. SETTINGS University hospital, Lariboisière Hospital, Paris. METHODS Thirty milligrams of morphine as a sustained-release formulation was orally administered in 12 women who had undergone RYGB for at least 2 years (RYGB group) and in their nonsurgical controls matched for sex, body mass index (±2 points), and age (±5 yr). Morphine, morphine-3-glucuronide, and morphine-6-glucuronide plasma concentrations over a 12-hour period were determined by a validated method using liquid chromatography mass spectrometry in tandem. Drowsiness, respiratory rate, and oxygen saturation were monitored during the PK visit. RESULTS Morphine oral area under the curve (for time 0-12 hr; 115.8 ± 108.0 nmol.hr/L and 86.9 ± 38.8 nmol.hr/L for RYGB group and control group, respectively, P = .71), morphine at maximal concentration, metabolites oral area under the curve (for time 0-12 hr), and other PK parameters were similar between groups. After drug administration, mean drowsiness was superior in RYGB group. Mean respiratory rate and oxygen saturation were similar in both groups. CONCLUSION No dose adjustment seems to be needed for sustained release morphine when prescribed to RYGB patients.
Collapse
Affiliation(s)
- Lorry Hachon
- Inserm U1144, Paris, France; Therapeutic Research Unit, Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Paris, France
| | - Rafael Reis
- Inserm U1144, Paris, France; Biologie du médicament et Toxicologie, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Laurence Labat
- Inserm U1144, Paris, France; Biologie du médicament et Toxicologie, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France; Université Paris Descartes, UMR-S 1144, Paris, France
| | - Christine Poitou
- Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Nutrition, Université Pierre et Marie Curie, Institut cardiométabolisme et nutrition (ICAN), Paris, France
| | - Aude Jacob
- Inserm U1144, Paris, France; Université Paris Descartes, UMR-S 1144, Paris, France
| | - Xavier Declèves
- Inserm U1144, Paris, France; Biologie du médicament et Toxicologie, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France; Université Paris Descartes, UMR-S 1144, Paris, France
| | - Celia Lloret-Linares
- Inserm U1144, Paris, France; Therapeutic Research Unit, Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Paris, France; Université Paris Diderot, UMR-S 1144, Paris, France.
| |
Collapse
|
40
|
Auvity S, Chapy H, Goutal S, Caillé F, Hosten B, Smirnova M, Declèves X, Tournier N, Cisternino S. Diphenhydramine as a selective probe to study H +-antiporter function at the blood-brain barrier: Application to [ 11C]diphenhydramine positron emission tomography imaging. J Cereb Blood Flow Metab 2017; 37:2185-2195. [PMID: 27488910 PMCID: PMC5464711 DOI: 10.1177/0271678x16662042] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Diphenhydramine, a sedative histamine H1-receptor (H1R) antagonist, was evaluated as a probe to measure drug/H+-antiporter function at the blood-brain barrier. In situ brain perfusion experiments in mice and rats showed that diphenhydramine transport at the blood-brain barrier was saturable, following Michaelis-Menten kinetics with a Km = 2.99 mM and Vmax = 179.5 nmol s-1 g-1. In the pharmacological plasma concentration range the carrier-mediated component accounted for 77% of diphenhydramine influx while passive diffusion accounted for only 23%. [14C]Diphenhydramine blood-brain barrier transport was proton and clonidine sensitive but was influenced by neither tetraethylammonium, a MATE1 (SLC47A1), and OCT/OCTN (SLC22A1-5) modulator, nor P-gp/Bcrp (ABCB1a/1b/ABCG2) deficiency. Brain and plasma kinetics of [11C]diphenhydramine were measured by positron emission tomography imaging in rats. [11C]Diphenhydramine kinetics in different brain regions were not influenced by displacement with 1 mg kg-1 unlabeled diphenhydramine, indicating the specificity of the brain positron emission tomography signal for blood-brain barrier transport activity over binding to any central nervous system target in vivo. [11C]Diphenhydramine radiometabolites were not detected in the brain 15 min after injection, allowing for the reliable calculation of [11C]diphenhydramine brain uptake clearance (Clup = 0.99 ± 0.18 mL min-1 cm-3). Diphenhydramine is a selective and specific H+-antiporter substrate. [11C]Diphenhydramine positron emission tomography imaging offers a reliable and noninvasive method to evaluate H+-antiporter function at the blood-brain barrier.
Collapse
Affiliation(s)
- Sylvain Auvity
- 1 Imagerie Moléculaire In Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France.,2 Variabilité de réponse aux psychotropes, INSERM, U1144, Paris, France; Université Paris Descartes, Faculté de pharmacie, UMR-S 1144, Paris, F-75006, France. Université Paris Diderot, UMR-S 1144, Paris, F-75013, France
| | - Hélène Chapy
- 2 Variabilité de réponse aux psychotropes, INSERM, U1144, Paris, France; Université Paris Descartes, Faculté de pharmacie, UMR-S 1144, Paris, F-75006, France. Université Paris Diderot, UMR-S 1144, Paris, F-75013, France
| | - Sébastien Goutal
- 1 Imagerie Moléculaire In Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France
| | - Fabien Caillé
- 1 Imagerie Moléculaire In Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France
| | - Benoit Hosten
- 2 Variabilité de réponse aux psychotropes, INSERM, U1144, Paris, France; Université Paris Descartes, Faculté de pharmacie, UMR-S 1144, Paris, F-75006, France. Université Paris Diderot, UMR-S 1144, Paris, F-75013, France
| | - Maria Smirnova
- 2 Variabilité de réponse aux psychotropes, INSERM, U1144, Paris, France; Université Paris Descartes, Faculté de pharmacie, UMR-S 1144, Paris, F-75006, France. Université Paris Diderot, UMR-S 1144, Paris, F-75013, France
| | - Xavier Declèves
- 2 Variabilité de réponse aux psychotropes, INSERM, U1144, Paris, France; Université Paris Descartes, Faculté de pharmacie, UMR-S 1144, Paris, F-75006, France. Université Paris Diderot, UMR-S 1144, Paris, F-75013, France
| | - Nicolas Tournier
- 1 Imagerie Moléculaire In Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France
| | - Salvatore Cisternino
- 1 Imagerie Moléculaire In Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France.,2 Variabilité de réponse aux psychotropes, INSERM, U1144, Paris, France; Université Paris Descartes, Faculté de pharmacie, UMR-S 1144, Paris, F-75006, France. Université Paris Diderot, UMR-S 1144, Paris, F-75013, France
| |
Collapse
|
41
|
Labat L, Declèves X. Le traitement de l’alcoolo-dépendance : aspects analytiques. Toxicologie Analytique et Clinique 2017. [DOI: 10.1016/j.toxac.2017.03.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
42
|
Shawahna R, Ganeshamoorthy K, Huilong L, Scherrmann JM, Couraud PO, Declèves X. Effect of Long-term In Vitro Lithium Exposure on mRNA Levels of Claudin-3, CYP1A1, ABCG2 and GSTM3 Genes in the hCMEC/D3 Human Brain Endothelial Cell Line. Eur J Drug Metab Pharmacokinet 2017; 42:1013-1017. [DOI: 10.1007/s13318-017-0412-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Lloret-Linares C, Luo H, Rouquette A, Labat L, Poitou C, Tordjman J, Bouillot JL, Mouly S, Scherrmann JM, Bergmann JF, Declèves X. The effect of morbid obesity on morphine glucuronidation. Pharmacol Res 2017; 118:64-70. [DOI: 10.1016/j.phrs.2016.08.031] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Revised: 08/29/2016] [Accepted: 08/29/2016] [Indexed: 01/28/2023]
|
44
|
Labat L, Goncalves A, Marques AR, Duretz B, Granger B, Declèves X. Liquid chromatography high resolution mass spectrometry for the determination of baclofen and its metabolites in plasma: Application to therapeutic drug monitoring. Biomed Chromatogr 2017; 31. [DOI: 10.1002/bmc.3936] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 01/09/2017] [Accepted: 01/11/2017] [Indexed: 12/20/2022]
Affiliation(s)
- Laurence Labat
- Biologie du Médicament et Toxicologie; Groupe Cochin (Assistance Publique - Hôpitaux de Paris); France
- Inserm UMR - S1144 Universités (Paris Descartes - Paris Diderot); France
| | - Antonio Goncalves
- Biologie du Médicament et Toxicologie; Groupe Cochin (Assistance Publique - Hôpitaux de Paris); France
| | - Ana Rita Marques
- Biologie du Médicament et Toxicologie; Groupe Cochin (Assistance Publique - Hôpitaux de Paris); France
| | | | - Bernard Granger
- Service de Psychiatrie, Hôpital Tarnier; Groupe Cochin (Assistance Publique - Hôpitaux de Paris); France
| | - Xavier Declèves
- Biologie du Médicament et Toxicologie; Groupe Cochin (Assistance Publique - Hôpitaux de Paris); France
- Inserm UMR - S1144 Universités (Paris Descartes - Paris Diderot); France
| |
Collapse
|
45
|
Kamilia C, Regaieg K, Baccouch N, Chelly H, Bahloul M, Bouaziz M, Jendoubi A, Abbes A, Belhaouane H, Nasri O, Jenzri L, Ghedira S, Houissa M, Belkadi K, Harti Y, Nsiri A, Khaleq K, Hamoudi D, Harrar R, Thieffry C, Wallet F, Parmentier-Decrucq E, Favory R, Mathieu D, Poissy J, Lafon T, Vignon P, Begot E, Appert A, Hadj M, Claverie P, Matt M, Barraud O, François B, Jamoussi A, Jazia AB, Marhbène T, Lakhdhar D, Khelil JB, Besbes M, Goutay J, Blazejewski C, Joly-Durand I, Pirlet I, Weillaert MP, Beague S, Aziz S, Hafiane R, Hattabi K, Bouhouri MA, Hammoudi D, Fadil A, Harrar RA, Zerouali K, Medhioub FK, Allela R, Algia NB, Cherif S, Slaoui MT, Boubia S, Hafiani Y, Khaoudi A, Cherkab R, Elallam W, Elkettani C, Barrou L, Ridaii M, Mehdi RE, Schimpf C, Mizrahi A, Pilmis B, Le Monnier A, Tiercelet K, Cherin M, Bruel C, Philippart F, Bailly S, Lucet J, Lepape A, L’hériteau F, Aupée M, Bervas C, Boussat S, Berger-Carbonne A, Machut A, Savey A, Timsit JF, Razazi K, Rosman J, de Prost N, Carteaux G, Jansen C, Decousser JW, Brun-Buisson C, Dessap AM, M’rad A, Ouali Z, Barghouth M, Kouatchet A, Boudon M, Ichai P, Younes A, Nakad L, Coilly A, Antonini T, Sobesky R, De Martin E, Samuel D, Hubert N, Mahieu R, Nay MA, Auchabie J, Giraudeau B, Jean R, Darmon M, Ruckly S, Garrouste-Orgeas M, Gratia E, Goldgran-Toledano D, Jamali S, Weiss E, Dumenil AS, Schwebel C, Brisard L, Bizouarn P, Lepoivre T, Nicolet J, Rigal JC, Roussel JC, Cheurfa C, Abily J, Schnell D, Lescot T, Page I, Warnier S, Nys M, Rousseau AF, Damas P, Uhel F, Lesouhaitier M, Grégoire M, Gaudriot B, Zahar JR, Gacouin A, Le Tulzo Y, Flecher E, Tarte K, Tadié JM, Georges Q, Soares M, Jeon K, Oeyen S, Rhee CK, Artiguenave M, Gruber P, Ostermann M, Hill Q, Depuydt P, Ferra C, Muller A, Aurelie B, Niles C, Herbert F, Pied S, Sophie PP, Loridant S, François N, Bignon A, Sendid B, Lemaitre C, Dupre C, Zayene A, Portier L, De Freitas Caires N, Lassalle P, Espinasse F, Le Neindre A, Selot P, Ferreiro D, Bonarek M, Henriot S, Rodriguez J, Taddei M, Di Bari M, Hickmann C, Castanares-Zapatero D, Sayed FE, Deldicque L, Van Den Bergh P, Caty G, Roeseler J, Francaux M, Laterre PF, Dupuis B, Machayeckhi S, Sarfati C, Moore A, Dinh A, Mendialdua P, Rodet E, Pilorge C, Stephan F, Rezaiguia-Delclaux S, Dugernier J, Hesse M, Jumetz T, Bialais E, Depoortere V, Charron C, Michotte JB, Wittebole X, Jamar F, Geri G, Vieillard-Baron A, Repessé X, Kallel H, Mayence C, Houcke S, Guegueniat P, Hommel D, Dhifaoui K, Hajjej Z, Fatnassi A, Sellami W, Labbene I, Ferjani M, Dachraoui F, Nakkaa S, M’ghirbi A, Adhieb A, Braiek DB, Hraiech K, Ousji A, Ouanes I, Zaineb H, Abdallah SB, Ouanes-Besbes L, Abroug F, Klein S, Miquet M, Thouret JM, Peigne V, Daban JL, Boutonnet M, Lenoir B, Merhbene T, Derreumaux C, Seguin T, Conil JM, Kelway C, Blasco V, Nafati C, Harti K, Reydellet L, Albanese J, Aicha NB, Meddeb K, Khedher A, Ayachi J, Fraj N, Sma N, Chouchene I, Boussarsar M, Yedder SB, Samoud W, Radhouene B, Mariem B, Ammar A, Cheikh AB, Lakhal HB, Khelfa M, Hamdaoui Y, Bouafia N, Trampont T, Daix T, Legarçon V, Karam HH, Pichon N, Essafi F, Foudhaili N, Thabet H, Blel Y, Brahmi N, Ezzouine H, Kerrous M, Haoui SE, Ahdil S, Benslama A, Abidi K, Dendane T, Oussama S, Belayachi J, Madani N, Abouqal R, Zeggwagh AA, Ghadhoune H, Chaari A, Jihene G, Allouche H, Trabelsi I, Brahmi H, Samet M, Ghord HE, Habiba BSA, Hajer N, Tilouch N, Yaakoubi S, Jaoued O, Gharbi R, Hassen MF, Elatrous S, Arcizet J, Leroy B, Abdulmalack C, Renzullo C, Hamet M, Doise JM, Coutet J, Cheikh CM, Quechar Z, Joris M, Beauport DT, Kontar L, Lebon D, Gruson B, Slama M, Marolleau JP, Maizel J, Gorham J, Ameye L, Berghmans T, Paesmans M, Sculier JP, Meert AP, Guillot M, Ledoux MP, Braun T, Maestraggi Q, Michard B, Castelain V, Herbrecht R, Schneider F, Couffin S, Lobo D, Mongardon N, Dhonneur G, Mounier R, Le Borgne P, Couraud S, Herbrecht JE, Boivin A, Lefebvre F, Bilbault P, Zelmat SA, Batouche DD, Mazour F, Chaffi B, Benatta N, Sik AH, Talik I, Perrier M, Gouteix E, Koubi C, Escavy A, Guilbaut V, Fosse JP, Jazia RB, Abdelghani A, Cungi PJ, Bordes J, Nguyen C, Pierrou C, Cruc M, Benois A, Duprez F, Bonus T, Cuvelier G, Ollieuz S, Machayekhi S, Paciorkowski F, Reychler G, Coudroy R, Thille AW, Drouot X, Diaz V, Meurice JC, Robert R, Turki O, Ben HC, Assefi M, Deransy R, Brisson H, Monsel A, Conti F, Scatton O, Langeron O, Ghezala HB, Snouda S, Ben CI, Kaddour M, Armel A, Youness L, Abdelhak B, Youssef M, Najib AH, Mustapha A, Noufel M, Mohamed Z, Salma EK, Ghizlane M, Mohamed B, Benyounes R, Montini F, Moschietto S, Gregoire E, Claisse G, Guiot J, Morimont P, Krzesinski JM, Mariat C, Lambermont B, Cavalier E, Delanaye P, Benbernou S, Ilies S, Azza A, Bouyacoub K, Louail M, Mokhtari-Djebli H, Arrestier R, Daviaud F, Francois XL, Brocas E, Choukroun G, Peñuelas O, Lorente JA, Cardinal-Fernandez P, Rodriguez JM, Aramburu JA, Esteban A, Frutos-Vivar F, Bitker L, Costes N, Le Bars D, Lavenne F, Devouassoux M, Richard JC, Mechati M, Gainnier M, Papazian L, Guervilly C, Garnero A, Arnal JM, Roze H, Richard JC, Repusseau B, Dewitte A, Joannes-Boyau O, Ouattara A, Harbouze N, Amine AM, Olandzobo AG, Herbland A, Richard M, Girard N, Lambron L, Lesieur O, Wainschtein S, Hubert S, Hugues A, Tran M, Bouillard P, Loteanu V, Leloup M, Laurent A, Lheureux F, Prestifilippo A, Cruz MDM, Romain R, Antonelli M, Blanch TL, Bonnetain F, Grazzia-Bocci M, Mancebo J, Samain E, Paul H, Capellier G, Zavgorodniaia T, Soichot M, Malissin I, Voicu S, Garçon P, Goury A, Kerdjana L, Deye N, Bourgogne E, Megarbane B, Mejri O, Hmida MB, Tannous S, Chevillard L, Labat L, Risede P, Fredj H, Léger M, Brunet M, Le Roux G, Boels D, Lerolle N, Farah S, Amiel-Niemann H, Kubis N, Declèves X, Peyraux N, Baud F, Serafini M, Alvarez JC, Heinzelman A, Jozwiak M, Millasseau S, Teboul JL, Alphonsine JE, Depret F, Richard N, Attal P, Richard C, Monnet X, Chemla D, Jerbi S, Khedhiri W, Necib H, Scarfo P, Chevalier C, Piagnerelli M, Lafont A, Galy A, Mancia C, Zerhouni A, Tabeliouna K, Gaja A, Hamrouni B, Malouch A, Fourati S, Messaoud R, Zarrouki Y, Ziadi A, Rhezali M, Zouizra Z, Boumzebra D, Samkaoui MA, Brunet J, Canoville B, Verrier P, Ivascau C, Seguin A, Valette X, Du Cheyron D, Daubin C, Bougouin W, Aissaoui N, Lamhaut L, Jost D, Maupain C, Beganton F, Bouglé A, Dumas F, Marijon E, Jouven X, Cariou A, Poirson F, Chaput U, Beeken T, Maxime L, Haikel O, Vodovar D, Chelly J, Marteau P, Chocron R, Juvin P, Loeb T, Adnet F, Lecarpentier E, Riviere A, De Cagny B, Soupison T, Privat E, Escutnaire J, Dumont C, Baert V, Vilhelm C, Hubert H, Leteurtre S, Fresco M, Bubenheim M, Beduneau G, Carpentier D, Grange S, Artaud-Macari E, Misset B, Tamion F, Girault C, Dumas G, Chevret S, Lemiale V, Mokart D, Mayaux J, Pène F, Nyunga M, Perez P, Moreau AS, Bruneel F, Vincent F, Klouche K, Reignier J, Rabbat A, Azoulay E, Frat JP, Ragot S, Constantin JM, Prat G, Mercat A, Boulain T, Demoule A, Devaquet J, Nseir S, Charpentier J, Argaud L, Beuret P, Ricard JD, Teiten C, Marjanovic N, Palamin N, L’Her E, Bailly A, Boisramé-Helms J, Champigneulle B, Kamel T, Mercier E, Le Thuaut A, Lascarrou JB, Rolle A, De Jong A, Chanques G, Jaber S, Hariri G, Baudel JL, Dubée V, Preda G, Bourcier S, Joffre J, Bigé N, Ait-Oufella H, Maury E, Mater H, Merdji H, Grimaldi D, Rousseau C, Mira JP, Chiche JD, Sedghiani I, Benabderrahim A, Hamdi D, Jendoubi A, Cherif MA, Hechmi YZE, Zouheir J, Bagate F, Bousselmi R, Schortgen F, Asfar P, Guérot E, Fabien G, Anguel N, Sigismond L, Matthieu HL, Gonzalez F, François L, Guitton C, Schenck M, Jean-Marc D, Dreyfuss D, Radermacher P, Frère A, Martin-Lefèvre L, Colin G, Fiancette M, Henry-Laguarrigue M, Lacherade JC, Lebert C, Vinatier I, Yehia A, Joret A, Menunier-Beillard N, Benzekri-Lefevre D, Desachy A, Bellec F, Plantefève G, Quenot JP, Meziani F, Tavernier E, Ehrmann S, Chudeau N, Raveau T, Moal V, Houillier P, Rouve E, Lakhal K, Gandonnière CS, Jouan Y, Bodet-Contentin L, Balmier A, Messika J, De Montmollin E, Pouyet V, Sztrymf B, Thiagarajah A, Roux D, De Chambrun MP, Luyt CE, Beloncle F, Zapella N, Ledochowsky S, Terzi N, Mazou JM, Sonneville R, Paulus S, Fedun Y, Landais M, Raphalen JH, Combes A, Amoura Z, Jacquemin A, Guerrero F, Marcheix B, Hernandez N, Fourcade O, Georges B, Delmas C, Makoudi S, Genton A, Bernard R, Lebreton G, Amour J, Mazet C, Bounes F, Murat G, Cronier L, Robin G, Biendel C, Silva S, Boubeche S, Abriou C, Wurtz V, Scherrer V, Rey N, Gastaldi G, Veber B, Doguet F, Gay A, Dureuil B, Besnier E, Rouget A, Gantois G, Magalhaes E, Wanono R, Smonig R, Lermuzeaux M, Lebut J, Olivier A, Dupuis C, Radjou A, Mourvillier B, Neuville M, D’ortho MP, Bouadma L, Rouvel-Tallec A, Rudler M, Weiss N, Perlbarg V, Galanaud D, Thabut D, Rachdi E, Mhamdi G, Trifi A, Abdelmalek R, Abdellatif S, Daly F, Nasri R, Tiouiri H, Lakhal SB, Rousseau G, Asmolov R, Grammatico-Guillon L, Auvet A, Laribi S, Garot D, Dequin PF, Guillon A, Fergé JL, Abgrall G, Hinault R, Vally S, Roze B, Chaplain A, Chabartier C, Savidan AC, Marie S, Cabie A, Resiere D, Valentino R, Mehdaoui H, Benarous L, Soda-Diop M, Bouzana F, Perrin G, Bourenne J, Eon B, Lambert D, Trebuchon A, Poncelet G, Le Bourgeois F, Michael L, Camille G, Naudin J, Deho A, Dauger S, Sauthier M, Bergeron-Gallant K, Emeriaud G, Jouvet P, Tiebergien N, Jacquet-Lagrèze M, Fellahi JL, Baudin F, Essouri S, Javouhey E, Guérin C, Lampin M, Mamouri O, Devos P, Karaca-Altintas Y, Vinchon M, Brossier D, Eltaani R, Teyssedre S, Sabine M, Bouchut JC, Peguet O, Petitdemange L, Guilbert AS, Aoul NT, Addou Z, Aouffen N, Anas B, Kalouch S, Yaqini K, Chlilek A, Abdou R, Gravellier P, Chantreuil J, Travers N, Listrat A, Le Reun C, Favrais G, Coppere Z, Blanot S, Montmayeur J, Bronchard R, Rolando S, Orliaguet G, Leger PL, Rambaud J, Thueux E, De Larrard A, Berthelot V, Denot J, Reymond M, Amblard A, Morin-Zorman S, Lengliné E, Pichereau C, Mariotte E, Emmanuel C, Poujade J, Trumpff G, Janssen-Langenstein R, Harlay ML, Zaid N, Ait-Ammar N, Bonnal C, Merle JC, Botterel F, Levesque E, Riad Z, Mezidi M, Yonis H, Aublanc M, Perinel-Ragey S, Lissonde F, Louf-Durier A, Tapponnier R, Louis B, Forel JM, Bisbal M, Lehingue S, Rambaud R, Adda M, Hraiech S, Marchi E, Roch A, Guerin V, Rozencwajg S, Schmidt M, Hekimian G, Bréchot N, Trouillet JL, Besset S, Franchineau G, Nieszkowska A, Pascal L, Loiselle M, Sarah C, Laurence D, Guillemette T, Jacquens A, Kerever S, Guidet B, Aegerter P, Das V, Fartoukh M, Hayon J, Desmard M, Fulgencio JP, Zuber B, Soufi A, Khaleq K, Hamoudi D, Garret C, Peron M, Coron E, Bretonnière C, Audureau E, Audrey W, Christophe D, Christian J, Daniel A, Cyrille F, Aissaoui W, Rghioui K, Haddad W, Barrou H, Carteaux-Taeib A, Lupinacci R, Manceau G, Jeune F, Tresallet C, Habacha S, Fathallah I, Zoubli A, Aloui R, Kouraichi N, Jouet E, Badin J, Fermier B, Feller M, Serie M, Pillot J, Marie W, Gisbert-Mora C, Vinclair C, Lesbordes P, Mathieu P, De Brabant F, Muller E, Robaux MA, Giabicani M, Marchalot A, Gelinotte S, Declercq PL, Eraldi JP, Bougerol F, Meunier-Beillard N, Devilliers H, Rigaud JP, Verrière C, Ardisson F, Kentish-Barnes N, Jacq G, Chermak A, Lautrette A, Legrand M, Soummer A, Thiery G, Cottereau A, Canet E, Caujolle M, Allyn J, Valance D, Brulliard C, Martinet O, Jabot J, Gallas T, Vandroux D, Allou N, Durand A, Nevière R, Delguste F, Boulanger E, Preau S, Martin R, Cochet H, Ponthus JP, Amilien V, Tchir M, Barsam E, Ayoub M, Georger JF, Guillame I, Assaraf J, Tripon S, Mallet M, Barbara G, Louis G, Gaudry S, Barbarot N, Jamet A, Outin H, Gibot S, Bollaert PE, Holleville M, Legriel S, Chateauneuf AL, Cavelot S, Moyer JD, Bedos JP, Merle P, Laine A, Natalie DS, Cornuault M, Libot J, Asehnoune K, Rozec B, Dantal J, Videcoq M, Degroote T, Jaillette E, Zerimech F, Malika B, Llitjos JF, Amara M, Lacave G, Pangon B, Mavinga J, Makunza JN, Mafuta ME, Yanga Y, Eric A, Ilunga J, Kilembe M, Alby-Laurent F, Toubiana J, Mokline A, Laajili A, Amri H, Rahmani I, Mensi N, Gharsallah L, Tlaili S, Gasri B, Hammouda R, Messadi AA, Allain PA, Gault N, Paugam-Burtz C, Foucrier A, Chatbri B, Bourbiaa Y, Thabet L, Neuschwander A, Vincent L, Beck J, Vibol C, Amelie Y, Resche-Rigon M, Pirracchio JM, Bureau C, Decavèle M, Campion S, Ainsouya R, Niérat MC, Prodanovic H, Raux M, Similowski T, Dubé BP, Demiri S, Dres M, May F, Quintard H, Kounis I, Saliba F, André S. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress. Ann Intensive Care 2017. [PMCID: PMC5225389 DOI: 10.1186/s13613-016-0224-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
46
|
Miyauchi E, Tachikawa M, Declèves X, Uchida Y, Bouillot JL, Poitou C, Oppert JM, Mouly S, Bergmann JF, Terasaki T, Scherrmann JM, Lloret-Linares C. Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects. Mol Pharm 2016; 13:2631-40. [DOI: 10.1021/acs.molpharmaceut.6b00085] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Eisuke Miyauchi
- Membrane Transport and Drug Targeting Laboratory,
Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan
| | - Masanori Tachikawa
- Membrane Transport and Drug Targeting Laboratory,
Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan
| | - Xavier Declèves
- Inserm, UMR-S 1144 Université Paris Descartes-Paris Diderot, Variabilité de réponse aux psychotropes, Paris F-75010, France
- Pharmacokinetics and Pharmacochemistry Unit, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris F-75014, France
| | - Yasuo Uchida
- Membrane Transport and Drug Targeting Laboratory,
Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan
| | - Jean-Luc Bouillot
- Department of Surgery, Université
Versailles Saint Quentin, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne 92100, France
| | - Christine Poitou
- Institut cardiométabolisme et nutrition
(ICAN), Université Pierre et Marie Curie, Service de Nutrition,
Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris F-75013, France
| | - Jean-Michel Oppert
- Institut cardiométabolisme et nutrition
(ICAN), Université Pierre et Marie Curie, Service de Nutrition,
Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris F-75013, France
| | - Stéphane Mouly
- Inserm, UMR-S 1144 Université Paris Descartes-Paris Diderot, Variabilité de réponse aux psychotropes, Paris F-75010, France
- Department of Internal Medicine, Therapeutic Research
Unit, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris F-75010, France
| | - Jean-François Bergmann
- Inserm, UMR-S 1144 Université Paris Descartes-Paris Diderot, Variabilité de réponse aux psychotropes, Paris F-75010, France
- Department of Internal Medicine, Therapeutic Research
Unit, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris F-75010, France
| | - Tetsuya Terasaki
- Membrane Transport and Drug Targeting Laboratory,
Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan
| | - Jean-Michel Scherrmann
- Inserm, UMR-S 1144 Université Paris Descartes-Paris Diderot, Variabilité de réponse aux psychotropes, Paris F-75010, France
| | - Célia Lloret-Linares
- Inserm, UMR-S 1144 Université Paris Descartes-Paris Diderot, Variabilité de réponse aux psychotropes, Paris F-75010, France
- Department of Internal Medicine, Therapeutic Research
Unit, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris F-75010, France
| |
Collapse
|
47
|
Mouly S, Bloch V, Peoc'h K, Houze P, Labat L, Ksouda K, Simoneau G, Declèves X, Bergmann JF, Scherrmann JM, Laplanche JL, Lepine JP, Vorspan F. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol 2016; 79:967-77. [PMID: 25556837 DOI: 10.1111/bcp.12576] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2014] [Revised: 12/05/2014] [Accepted: 12/21/2014] [Indexed: 01/11/2023] Open
Abstract
AIMS Methadone is characterized by wide intersubject variability regarding the dose needed to obtain full therapeutic response. We assessed the influence of sociodemographic, ethnic, clinical, metabolic and genotypic variables on methadone maintenance dose requirement in opioid-dependent responder patients. METHODS Eighty-one stable patients (60 men and 21 women, 43.7 ± 8.1 years old, 63.1 ± 50.9 mg day(-1) methadone), divided into quartiles with respect to the median daily dose, were enrolled and underwent clinical examination, treatment history and determination of liver/intestinal cytochrome P450 (CYP) 3A4 activity measured by the midazolam test, R,S-methadone trough concentration and clinically significant polymorphisms of the OPRM1, DRD2, COMT, ABCB1, CYP2B6, CYP3A5, CYP2C19 and CYP2D6 genes. RESULTS Methadone maintenance dose was correlated to the highest dose ever used (r(2) = 0.57, P < 0.0001). Fractioned methadone intake (odds ratio 4.87, 95% confidence interval 1.27-18.6, P = 0.02), bodyweight (odds ratio 1.57, 95% confidence interval 1.01-2.44, P = 0.04), history of cocaine dependence (80 vs. 44 mg day(-1) in never-addict patients, P = 0.005) and ethnicity (Asian > Caucasian > African, P = 0.04) were independently associated with high-dose methadone in multiple regression analysis. A modest correlation was observed between liver/intestinal CYP3A4 activity and methadone dose at steady state (Spearman rank correlation coefficient [rs ] = 0.21, P = 0.06) but not with highest dose ever used (rs = 0.15, P = 0.18) or dose-normalized R,S-methadone trough concentrations (rs = -0.05, P = 0.64). Concomitant CYP3A4 inhibitors only affected the relationship between methadone dose and R,S-methadone trough concentration. None of the genetic polymorphisms explored was predictive of the methadone maintenance dose. CONCLUSIONS Methadone maintenance dose was predicted by sociodemographic and clinical variables rather than genetic polymorphisms or liver/intestinal CYP3A4 activity in stable patients.
Collapse
Affiliation(s)
- Stéphane Mouly
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France.,Unit of Therapeutic Research & Internal Medicine Department, Lariboisière-Saint Louis Hospital, Paris, France
| | - Vanessa Bloch
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France
| | - Katell Peoc'h
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France.,Laboratory of Biochemistry and Molecular Biology, Lariboisière-Saint Louis Hospital, Paris, France
| | - Pascal Houze
- Laboratory of Pharmacology, Lariboisière-Saint Louis Hospital, Paris, France
| | - Laurence Labat
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France
| | - Kamilia Ksouda
- Psychiatric Unit, Assistance Publique-Hôpitaux de Paris (APHP), Lariboisière-Saint Louis Hospital, Paris, France
| | - Guy Simoneau
- Unit of Therapeutic Research & Internal Medicine Department, Lariboisière-Saint Louis Hospital, Paris, France
| | - Xavier Declèves
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France
| | - Jean Francois Bergmann
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France.,Unit of Therapeutic Research & Internal Medicine Department, Lariboisière-Saint Louis Hospital, Paris, France
| | - Jean-Michel Scherrmann
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France
| | - Jean-Louis Laplanche
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France.,Laboratory of Biochemistry and Molecular Biology, Lariboisière-Saint Louis Hospital, Paris, France
| | - Jean-Pierre Lepine
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France.,Psychiatric Unit, Assistance Publique-Hôpitaux de Paris (APHP), Lariboisière-Saint Louis Hospital, Paris, France
| | - Florence Vorspan
- Inserm, U1144, Paris, F-75006, France.,Université Paris Descartes, UMR-S1144, Paris, F-75006, France.,Université Paris Diderot, UMR-S1144, Paris, F-75010, France.,Psychiatric Unit, Assistance Publique-Hôpitaux de Paris (APHP), Lariboisière-Saint Louis Hospital, Paris, France
| |
Collapse
|
48
|
Dallas S, Salphati L, Gomez-Zepeda D, Wanek T, Chen L, Chu X, Kunta J, Mezler M, Menet MC, Chasseigneaux S, Declèves X, Langer O, Pierre E, DiLoreto K, Hoft C, Laplanche L, Pang J, Pereira T, Andonian C, Simic D, Rode A, Yabut J, Zhang X, Scheer N. Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model. Mol Pharmacol 2016; 89:492-504. [PMID: 26893303 DOI: 10.1124/mol.115.102079] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Accepted: 02/17/2016] [Indexed: 12/17/2022] Open
Abstract
Breast cancer resistance protein (BCRP) is expressed in various tissues, such as the gut, liver, kidney and blood brain barrier (BBB), where it mediates the unidirectional transport of substrates to the apical/luminal side of polarized cells. Thereby BCRP acts as an efflux pump, mediating the elimination or restricting the entry of endogenous compounds or xenobiotics into tissues and it plays important roles in drug disposition, efficacy and safety. Bcrp knockout mice (Bcrp(-/-)) have been used widely to study the role of this transporter in limiting intestinal absorption and brain penetration of substrate compounds. Here we describe the first generation and characterization of a mouse line humanized for BCRP (hBCRP), in which the mouse coding sequence from the start to stop codon was replaced with the corresponding human genomic region, such that the human transporter is expressed under control of the murineBcrppromoter. We demonstrate robust human and loss of mouse BCRP/Bcrp mRNA and protein expression in the hBCRP mice and the absence of major compensatory changes in the expression of other genes involved in drug metabolism and disposition. Pharmacokinetic and brain distribution studies with several BCRP probe substrates confirmed the functional activity of the human transporter in these mice. Furthermore, we provide practical examples for the use of hBCRP mice to study drug-drug interactions (DDIs). The hBCRP mouse is a promising model to study the in vivo role of human BCRP in limiting absorption and BBB penetration of substrate compounds and to investigate clinically relevant DDIs involving BCRP.
Collapse
Affiliation(s)
- Shannon Dallas
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Laurent Salphati
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - David Gomez-Zepeda
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Thomas Wanek
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Liangfu Chen
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Xiaoyan Chu
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Jeevan Kunta
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Mario Mezler
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Marie-Claude Menet
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Stephanie Chasseigneaux
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Xavier Declèves
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Oliver Langer
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Esaie Pierre
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Karen DiLoreto
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Carolin Hoft
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Loic Laplanche
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Jodie Pang
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Tony Pereira
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Clara Andonian
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Damir Simic
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Anja Rode
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Jocelyn Yabut
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Xiaolin Zhang
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| | - Nico Scheer
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)
| |
Collapse
|
49
|
Lloret-Linares C, Miyauchi E, Luo H, Labat L, Bouillot JL, Poitou C, Oppert JM, Laplanche JL, Mouly S, Scherrmann JM, Uchida Y, Tachikawa M, Terasaki T, Bergmann JF, Declèves X. Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers. Mol Pharm 2016; 13:766-73. [DOI: 10.1021/acs.molpharmaceut.5b00656] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Célia Lloret-Linares
- Inserm, UMR-S
1144 Université Paris Descartes-Paris Diderot, Variabilité
de réponse aux psychotropes, Paris F-75010, France
- Assistance Publique-Hôpitaux
de Paris, Hôpital Lariboisière, Therapeutic Research
Unit, Department of Internal Medicine, Paris F-75010, France
| | - Eisuke Miyauchi
- Membrane
Transport and Drug Targeting Laboratory, Graduate School of Pharmaceutical
Sciences, Tohoku University, Sendai 980-8578, Japan
| | - Huilong Luo
- Inserm, UMR-S
1144 Université Paris Descartes-Paris Diderot, Variabilité
de réponse aux psychotropes, Paris F-75010, France
- Assistance Publique-Hôpitaux
de Paris, Hôpital Cochin, Pharmacokinetics and Pharmacochemistry
Unit, Paris F-75014, France
| | - Laurence Labat
- Inserm, UMR-S
1144 Université Paris Descartes-Paris Diderot, Variabilité
de réponse aux psychotropes, Paris F-75010, France
- Assistance Publique-Hôpitaux
de Paris, Hôpital Cochin, Pharmacokinetics and Pharmacochemistry
Unit, Paris F-75014, France
| | - Jean-Luc Bouillot
- Assistance Publique-Hôpitaux
de Paris, Hôpital Ambroise Paré, Université Versailles
Saint Quentin, Department of Surgery, Boulogne 92100, France
| | - Christine Poitou
- Assistance Publique-Hôpitaux
de Paris, Groupe Hospitalier Pitié-Salpêtrière,
Service de Nutrition, Université Pierre et Marie Curie, Institut
cardiométabolisme et nutrition (ICAN), Paris F-75013, France
| | - Jean-Michel Oppert
- Assistance Publique-Hôpitaux
de Paris, Groupe Hospitalier Pitié-Salpêtrière,
Service de Nutrition, Université Pierre et Marie Curie, Institut
cardiométabolisme et nutrition (ICAN), Paris F-75013, France
| | - Jean-Louis Laplanche
- Inserm, UMR-S
1144 Université Paris Descartes-Paris Diderot, Variabilité
de réponse aux psychotropes, Paris F-75010, France
| | - Stéphane Mouly
- Inserm, UMR-S
1144 Université Paris Descartes-Paris Diderot, Variabilité
de réponse aux psychotropes, Paris F-75010, France
- Assistance Publique-Hôpitaux
de Paris, Hôpital Lariboisière, Therapeutic Research
Unit, Department of Internal Medicine, Paris F-75010, France
| | - Jean-Michel Scherrmann
- Inserm, UMR-S
1144 Université Paris Descartes-Paris Diderot, Variabilité
de réponse aux psychotropes, Paris F-75010, France
| | - Yasuo Uchida
- Membrane
Transport and Drug Targeting Laboratory, Graduate School of Pharmaceutical
Sciences, Tohoku University, Sendai 980-8578, Japan
| | - Masanori Tachikawa
- Membrane
Transport and Drug Targeting Laboratory, Graduate School of Pharmaceutical
Sciences, Tohoku University, Sendai 980-8578, Japan
| | - Tetsuya Terasaki
- Membrane
Transport and Drug Targeting Laboratory, Graduate School of Pharmaceutical
Sciences, Tohoku University, Sendai 980-8578, Japan
| | - Jean-François Bergmann
- Inserm, UMR-S
1144 Université Paris Descartes-Paris Diderot, Variabilité
de réponse aux psychotropes, Paris F-75010, France
- Assistance Publique-Hôpitaux
de Paris, Hôpital Lariboisière, Therapeutic Research
Unit, Department of Internal Medicine, Paris F-75010, France
| | - Xavier Declèves
- Inserm, UMR-S
1144 Université Paris Descartes-Paris Diderot, Variabilité
de réponse aux psychotropes, Paris F-75010, France
- Assistance Publique-Hôpitaux
de Paris, Hôpital Cochin, Pharmacokinetics and Pharmacochemistry
Unit, Paris F-75014, France
| |
Collapse
|
50
|
Chapy H, Saubaméa B, Tournier N, Bourasset F, Behar-Cohen F, Declèves X, Scherrmann JM, Cisternino S. Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier. Br J Pharmacol 2016; 173:497-510. [PMID: 26507673 DOI: 10.1111/bph.13376] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Revised: 09/30/2015] [Accepted: 10/05/2015] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND AND PURPOSE The respective impact and interplay between ABC (P-glycoprotein/P-gp/Abcb1a, BCRP/ABCG2, MRP/ABCC) and SLC transporter functions at the blood-brain barrier (BBB) and blood-retinal barriers (BRB) are incompletely understood. EXPERIMENTAL APPROACH We measured the initial cerebral and retinal distribution of selected ABC substrates by in situ carotid perfusion using P-gp/Bcrp knockout mice and chemical ABC/SLC modulation strategies. P-gp, Bcrp, Mrp1 and Mrp4 were studied by confocal retina imaging. KEY RESULTS Chemical or physical disruption of P-gp increased [(3) H]-verapamil transport by ~10-fold at the BBB and ~1.5-fold at the BRB. [(3) H]-Verapamil transport involved influx-mediated by an organic cation clonidine-sensitive/diphenhydramine-sensitive proton antiporter at both barriers; this effect was unmasked when P-gp was partially or fully inhibited/disrupted at the BBB. Studies of [(3) H]-mitoxantrone and [(3) H]-zidovudine transport suggested, respectively, that Bcrp efflux was less involved at the BRB than BBB, whereas Mrps were significantly and similarly involved at both barriers. Confocal imaging showed that P-gp and Bcrp were expressed in intra-retinal vessels (inner BRB/iBRB) but absent from the blood/basal membrane of cells of the retinal pigment epithelium (outer BRB/oBRB/RPE) where, in contrast, Mrp1 and Mrp4 were localized. CONCLUSIONS AND IMPLICATIONS P-gp, Bcrp, Mrp1 and Mrp4 are differentially expressed at the outer and inner BRB, resulting in an altered ability to limit substrate distribution at the retina as compared with the BBB. [(3) H]-Verapamil distribution is not P-gp-specific and involves a proton antiporter at both the BBB and BRB. However, this transport is concealed by P-gp at the BBB, but not at the BRB, where P-gp activity is reduced.
Collapse
Affiliation(s)
- Hélène Chapy
- Variabilité de Réponse aux Psychotropes, INSERM, U1144, Paris, France.,Faculté de Pharmacie, Université Paris Descartes, UMR-S 1144, Paris, France.,Université Paris Diderot, UMR-S 1144, Paris, France
| | - Bruno Saubaméa
- Variabilité de Réponse aux Psychotropes, INSERM, U1144, Paris, France.,Faculté de Pharmacie, Université Paris Descartes, UMR-S 1144, Paris, France.,Université Paris Diderot, UMR-S 1144, Paris, France
| | - Nicolas Tournier
- INSERM, CEA, Université Paris Sud, UMR 1023 - ERL 9218 CNRS, IMIV, Orsay, France
| | - Fanchon Bourasset
- Variabilité de Réponse aux Psychotropes, INSERM, U1144, Paris, France.,Faculté de Pharmacie, Université Paris Descartes, UMR-S 1144, Paris, France.,Université Paris Diderot, UMR-S 1144, Paris, France
| | - Francine Behar-Cohen
- Université Paris Descartes, UMR-S 1138, Paris, France.,Physiopathologies des Maladies Oculaires, INSERM U1138, Paris, France
| | - Xavier Declèves
- Variabilité de Réponse aux Psychotropes, INSERM, U1144, Paris, France.,Faculté de Pharmacie, Université Paris Descartes, UMR-S 1144, Paris, France.,Université Paris Diderot, UMR-S 1144, Paris, France.,Assistance Publique des Hôpitaux de Paris - AP-HP, Paris, France
| | - Jean-Michel Scherrmann
- Variabilité de Réponse aux Psychotropes, INSERM, U1144, Paris, France.,Faculté de Pharmacie, Université Paris Descartes, UMR-S 1144, Paris, France.,Université Paris Diderot, UMR-S 1144, Paris, France.,Assistance Publique des Hôpitaux de Paris - AP-HP, Paris, France
| | - Salvatore Cisternino
- Variabilité de Réponse aux Psychotropes, INSERM, U1144, Paris, France.,Faculté de Pharmacie, Université Paris Descartes, UMR-S 1144, Paris, France.,Université Paris Diderot, UMR-S 1144, Paris, France.,Assistance Publique des Hôpitaux de Paris - AP-HP, Paris, France
| |
Collapse
|